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ABSTRACT 
A breast tumor with a histology report that lacks Estrogen Receptor, Progesterone 
Receptor, and Human Epidermal Growth Receptor 2/neu is identified as a Triple 
Negative Breast Cancer (TNBC). Women with TNBC compared to non-TNBC patients 
have 50% increased risk for all-cause mortality and TNBC is reported to have poor 
survival compared to other Breast Cancer sub-types. TNBC is an aggressive disease with 
varied outcomes among race/ethnicities in the United States. 
Chapter one is an introduction chapter that introduces the problem statement, 
highlights the significance of the problem, provides the theoretical framework along with 
its constructs and how it supports the proposed research.  
Chapter two is a review of the available published literature on TNBC, its phenotype 
and genotype, risk factors and ethnic differences among women of color. The literature 
search covered a span of ten years’ articles published in the online journals such as 
PubMed, CINAHL, Web of Science, and Medline and retrieved selected 85 journal 
articles. The review also provides information on ethnic similarities and differences for 
early detection, prevention, and treatment of TNBC.  
Chapter three is a research article and the purpose of that chapter is to provide the 
research questions and hypotheses related to specific aim one and two. Specific aim one 
is to provide the age-adjusted and age-specific incidence rates on TNBC among major 
races/ethnicities such as Non-Hispanic White, Non-Hispanic Black, Hispanic (all Races), 
and Asian Pacific Islander. The study sample included all 18 registries of Surveillance 
Epidemiology, and End Results. The chapter also provides TNBC phenotypic, 
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demographic, and treatment characteristics among TNBC cases and ethnic differences 
among them. For specific aim two, the sample includes five Asian sub-ethnicities, 
Chinese, Asian Indian, Vietnamese, Filipina, and Korean women along with 
Non-Hispanic White, Non-Hispanic Black and Hispanic women.   
Chapter four discusses the research findings and discussion on TNBC compared to 
non-TNBC cases, results from a binary regression model to predict TNBC risk among 
women of color. Odds Ratio for significant variables to predict TNBC risk are presented. 
Chapter five summarizes the dissertation by providing main findings and discussions. 
The limitations of the research study are presented and recommendations from the study 
are discussed. Finally, research implications developed from the study are listed. 
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CHAPTER 1 
INTRODUCTION 
This dissertation focuses on the problem of triple negative breast cancer in women of 
color. Chapter two will present a synthesis of research literature related to TNBC, risk 
factors, ethnic differences for TNBC incidence rates, risk factors, with identification of 
early detection methods, prevention, and treatment of TNBC recognized and used among 
women of color. In Chapter three, research on TNBC incidence rates as well as 
demographics, phenotypic and treatment characteristics of TNBC will be presented. The 
Dissertation Research on identifying risk factors associated with TNBC and a discussion 
of the prediction model to identify TNBC risk will be described in chapter four. Finally, 
Chapter 5 summarizes the main findings of the dissertation research, with a discussion 
about the limitations, recommendations and a discussion of how this research contributes 
to existing knowledge of TNBC in women of color. 
Statement of The Problem 
A breast tumor with a histology report that lacks Estrogen Receptor, Progesterone 
Receptor, and is Human Epidermal Growth Receptor 2/neu negative is identified as a 
Triple Negative Breast Cancer (TNBC) (Goldhirsch et al., 2011). Patients designated as 
TNBC compared to non-TNBC patients have a 50% increased risk for all-cause mortality. 
TNBC has been significantly associated with non-Breast Cancer mortality such as 
circulatory system diseases, other cancers or causes (Hazard Ratio/HR = 2.52, 95% C.I. = 
1.71-3.70, p < 0.05) and Breast Cancer- specific mortality (HR = 3.04, 95% C.I. = 
2.33-3.97, p < 0.05) (Lian et al., 2014).  
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TNBC is reported to have poorer survival compared to other sub-types. TNBC cases 
have been shown to be 200% significantly more likely to die of their disease compared to 
other hormone/HER2 groups, after adjustment for age at diagnosis and stage at 
presentation (p < 0.0001) (Matt, Mozayen, Gress, & Tirona, 2015). When TNBC women 
were assessed for five years’ survival, there was a significant decrease for both local 
(stage I and II) and regional disease (stage III) (p = 0.03 and 0.02 respectively), compared 
to all other hormone/HER2 groups (Matt et al., 2015). A similar pattern has been 
observed for TNBC stage IV disease as well (Matt et al.). The overall survival reported 
by Lin et al., (2012) using National Comprehensive Cancer Network data was worse than 
reported by Matt et al., (adjusted HR = 2.72, 95% C.I. =2.39-3.10). Other studies also 
reported similar results to Matt et al.’s findings that survival for TNBC is worst compared 
to other hormone sub-types (Parise & Caggiano, 2011; Bauer, Brown, Cress, Parise, & 
Caggiano, 2007). 
Among breast cancer cases, ethnic differences have been noted for TNBC survival 
statistics. Hispanic women are four times more likely to die from TNBC compared to 
HR+/HER2- women (Hazard Ratio = 4.05, 95% CI:3.35–4.90) (Banegas et al., 2014). 
African American women also have been found to have higher mortality from TNBC 
compared to Non-African American women (Christiansen, Chen, Gilmore, Pechar, & 
Szabo, 2012) other breast cancer sub-types (Bauer et al., 2007). These women in addition 
to poor survival have high breast cancer recurrence rate. Christiansen et al. (2012) reported 
significantly higher 5-year recurrence rate for African Americans, 42.5% compared to 7% 
among non-African Americans (p = 0.0005).  
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Compared to Non-Hispanic White women, combined Asian/Pacific Islander women 
(included Pacific Islander, Southeast Asian, Indian continent, Chinese, Japanese, Filipino, 
Korean) had decreased mortality (HR = 0.84, 95% C.I. = 0.74 - 0.94) (Parise & Caggiano, 
2016). The same study found significantly better survival rates for Asians (sub-ethnicities 
combined) when compared to White women (p = 0.025) (Parise & Caggiano, 2016). Hence 
TNBC is an aggressive disease with varied outcomes among races/ethnicities in the United 
States. This dissertation research and other chapter information provide available literature 
related to the problem statement and research study findings on assessment for differences 
in TNBC incidence rates among Non-Hispanic White, Non-Hispanic Black, Hispanic (all 
races), Chinese, Asian Indian, Vietnamese, Korean and Filipina women. Also, examination 
of associations between phenotypic, demographic, and treatment variables of TNBC 
among these eight groups of women, and how significant variables can be used to predict 
TNBC risk among these women will be provided. The new information will help to 
identify and focus on the plausible reasons for poor TNBC survival statistics among the 
women of color. 
Significance of The Problem 
The National Cancer Database’ (Plasilova et al., 2016) described female invasive 
breast cancers (n = 295,801) in U.S. women diagnosed between 2010-2011, and showed 
TNBC ranked second in frequency after HR+ HER2- subtype. Similar findings on TNBC 
ranking among other breast cancer subtypes was reported by (Llanos et al., 2015; Lund et 
al., 2009). The most recent TNBC age-adjusted incidence rate for all TNBC cases 
diagnosed in 2011 was 15.5 per 100,000 women for cases diagnosed in 2011 (Kohler et 
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al., 2015). Published information on incidence rate for TNBC cases diagnosed is not 
available since 2011.  
The race/ethnic groups in Kohler et al.’s study was NH White, NH Black, Hispanics, 
NH Asian/Pacific Islander. The TNBC age-adjusted rate was highest among 
Non-Hispanic (NH) Black followed by NH White, Hispanics and NH Asian/Pacific 
Islander (27.2, 14.4, 11.8, 10.3 per 100,000 person-years respectively) for the year 2011 
(Kohler et al., 2015). However, rates were not available for Asian sub-groups. The Asian 
female population is predicted to be approximately 7.7 million in 2020 (Projections of the 
Asian alone population by age and sex for the United States: 2010 to 2050, 2014) and 
based on TNBC frequency published by recent studies, approximately 11% of breast 
cancer cases will be affected by TNBC (Plasilova et al., 2016). The predicted number is 
8,342 to be diagnosed with TNBC who are Asian in the year 2020. Similarly, higher 
numbers for NH Black, Hispanics and NH White can be predicted since their reported 
TNBC frequencies are higher than Asian population (23.7%, 14.8%, 11.4%, respectively) 
(Plasilova et al., 2016). These numbers signify the magnitude of TNBC. 
Patients with TNBC compared to Non-TNBC patients experience increased number 
of hospitalized days, increased number of emergency room visits and significantly (p < 
0.0001) increased healthcare costs (Baser, Wei, Henk, Teitelbaum, & Xie, 2012). These 
factors are an important reason for the high mortality risk faced by the TNBC women; 
twice that of the Non-TNBC women (HR = 2.02, p < 0.0001) (Baser et al., 2012). The 
predicted high TNBC frequency plus the increased healthcare costs portray the burden of 
the disease for the public health system. In addition, the National Cancer Institute also 
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affirmed that cancer burden has a significant impact on public health in the United States. 
This institution also predicted that as the U.S. population continues to grow and age, 
cancer’s impact on public health would continue to grow (Cancer and Public health, 
2015).  
Theoretical Framework 
The Health Belief Model (HBM) was used as the theoretical framework for this 
TNBC dissertation research (Hochbaum, 1958). Since TNBC is a known aggressive 
cancer and believed to have an impact on public health, one of the ways for researchers to 
address the issue is by using available large registries that have information about people 
with cancer (Cancer and Public Health, 2015). This cancer specific information on 
population groups can be used to detect trends that affect cancer patients and to identify 
contribution of genetic factors, occupational, environmental, medical, and others to 
cancer risk (Cancer and Public Health, 2015).  
The HBM originally proposed that personal beliefs or perceptions about a disease 
and strategies to decrease the disease occurrence could determine health behavior 
(Hochbaum, 1958). HBM is a Mid-Range theory as it lies between everyday working 
hypothesis and all-inclusive grand theories. Due to this property, the HBM has more 
direct application to research and practice. Because of these qualities, the HBM has its 
application for Healthcare Genetics research. It could be applied in a clinical setting for 
assessing the perceptions, attitudes, and beliefs people have towards genetic testing. 
Another use would be in conjunction with the cancer risk assessment models used in 
research to assess the change in health behavior of individuals. Both quantitative and 
6 
 
qualitative studies have the potential to incorporate the HBM across a wide range of 
disease phenotypes. 
Originally in the 1950s four theoretical constructs were used in the HBM model: 
perceived seriousness, perceived susceptibility, perceived benefits, and perceived barriers. 
Since then additional constructs have been added to the model; cues to action, motivating 
factors, and self-efficacy.  
Perceived Severity 
The construct of perceived severity relates to an individual’s belief about the 
seriousness or severity of a disease. A person in general may have beliefs about 
difficulties a disease would create in one’s life and this along with medical information 
and knowledge constitutes the perception of seriousness (Glanz, Lewis, & Rimer, 1997).   
Perceived Susceptibility 
The second construct identifies powerful perceptions as susceptibility or personal 
risk and drives individuals to either adopt or abandon a behavior. Individuals can 
perceive to have higher risk for a one specific disease and will engage in healthy behavior 
and vice versa. The higher the risk perceived the increased likelihood of adopting healthy 
behaviors (Glanz, Lewis, & Rimer, 1997).   
Perceived Benefits 
Perceived benefits are the construct is that guides determination if a person would 
have an opinion that a new behavior has usefulness and decreases the risk for a disease. 
When people adopt a new behavior, they believe that the healthy behavior will decrease 
their chance of developing a disease and they strive to follow that behavior. This 
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construct has an important role to play in adoption of secondary prevention behaviors 
(Glanz, Lewis, & Rimer, 1997).  
Perceived Barriers 
This added construct is the individual’s own assessment of the obstacles that hinder 
them from adopting a healthy behavior. Perceived barriers are very significant in 
determining a behavior change (Janz & Becker, 1984; Glanz, Lewis, & Rimer, 1997). An 
individual can perceive the seriousness of the disease, but the barriers would prevent one 
from adopting a healthy behavior.  
Cues to Action 
Any event, person, or a thing that moves a person to change a behavior is a cue to 
action. This construct could be an illness of a family member, media report, mass media 
campaign, advice from others, reminder postcards from a health care provider, or a health 
warning label on a product (Glanz, Lewis, & Rimer, 1997).  
Self-Efficacy 
Self-efficacy is the construct that describes a belief in one’s own ability to do 
accomplish something in life. For example, without self-efficacy even if an individual 
perceives the seriousness of a disease but does not believe that he/she can adopt a healthy 
behavior, the new behavior will never be tried (Glanz, Lewis, & Rimer, 1997).   
Health Belief Model Assumptions 
The three assumptions that an individual will adopt a healthy behavior are: a) the 
person believes that a negative health condition can be avoided; b) the person has a high 
positive expectation that by engaging in a healthy behavior, one can avoid the negative 
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health condition; and, c) the person believes that he/she can perform the healthy behavior 
(Assumptions of HBM, 2017). 
The HBM has potential links between theory, research, and practice. It meets the 
criterion to be theory as it has a set of interrelated constructs, and it measures a systematic 
view of a phenomenon (perceptions) for predicting a behavior. The approach of the HBM 
to science is deductive in nature that it starts with a bigger picture and moves to the 
details. The constructs are more abstract as they are perceptions. All constructs have their 
conceptual and operational definitions. From its name, it is known that it is a model and a 
model is a symbolic representation of a set of concepts, created to depict relationships, it 
allows for investigation of the properties of the system and prediction of future outcomes. 
The Health Belief Model guides the research in two ways. Firstly, a person can 
perceive their susceptibility when cancer statistics are available and specific to them. For 
example, an Asian American woman might know her susceptibility only when an 
incidence rate is available on her population along with other related factors like age, 
income level, insurance status, and others. Secondly, when an individual perceives the 
seriousness of a disease, self-efficacy plays a role if there is belief in one’s own ability to 
do something. For example, a woman with higher TNBC risk can opt for early detection 
or prevention of the disease. 
The HBM guides the research to focus on areas of “perceived severity” and 
“perceived susceptibility.” Research variables such as TNBC tumor sizes, tumor stage, 
tumor grade, lymph node invasion, and metastasis corresponds to the construct of 
perceived severity of the disease and race/ethnicity, TNBC incidence rates, age at 
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diagnosis, insurance status, median household income level while TNBC frequency 
relates to the construct of perceived susceptibility of the disease. These two constructs of 
the HBM guide our research purpose. 
Review of Literature 
TNBC frequency is varied among races/ethnicities. The NH Black women ranked 
first in TNBC frequency followed by Hispanic, NH White, and NH Asian/Pacific 
Islander groups (23.7%, 14.8%, 11.4%, 11.2% respectively) (Plasilova et al., 2016). 
When individual ethnicities were compared, the study reported the following frequencies: 
Black women (23.7%) followed by Asian Indian (15.6%), American Indian/Eskimo 
(14.6%), Chinese (11.9%), Vietnamese (11.5%), Japanese (11.3%), and Filipino (8.9%) 
rank in TNBC tumor frequency (p < 0.01 when compared to White women and 
Non-TNBC tumors) (Plasilova et al., 2016). However, the incidences in Korean, Chinese, 
Vietnamese, and Japanese women were non-significant when compared to Non-TNBC 
and white women (Plasilova et al., 2016). Although it was observed that grouped Asian 
ethnicities had the lowest frequency compared to NH Black, NH White and Hispanics, 
when grouped individually the Asian ethnicities frequency rates were found to be higher.  
Clinico-pathologic features of TNBC were also found to be associated with 
race/ethnicity. Staging was an important variable and is based on primary Tumor (T), 
regional lymph Nodes (N), and distant Metastases (M) See Appendix A for American 
Joint Committee on Cancer staging manual 7th edition. Tao, Gomez, Keegan, Kurian, & 
Clarke (2015) used California Cancer Registry data and showed that African American 
women with Stage III TNBC had higher hazards of breast cancer death compared to 
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Whites (n=103,498) after adjusting for tumor characteristics, first course of treatment, 
neighborhood Socio Economic Status (SES) and insurance status (Tao et al., 2015). 
When stratified by SES, Hispanic women in the lower quintile had a higher Hazard Ratio 
for breast cancer-specific mortality than women from the highest quintile (Hazard 
Ratio=1.76 versus 1.38 respectively) (Banegas et al., 2014). These statistics highlight the 
greater TNBC risk for certain ethnic groups based on SES. More risk factors associated 
with TNBC include age at diagnosis, insurance status, family history, reproductive 
factors, BRCA mutation, and others. 
Ethnic differences in prevention, early detection, and treatment have been published 
in the literature. Healthcare provider referral and race/ethnicity were documented to be 
significant factors in getting genetic testing done (Thompson et al., 2012; Cragun et al., 
2015; Ricks-Santi & McDonald, 2016). Factors associated with healthcare provider 
referral for genetic testing and receiving genetic counseling were investigated in two 
studies. Healthcare provider referral, household income greater than $35,000 in the year 
prior to diagnosis, and insured with a private health insurance were strong predictors for 
receiving a genetic counseling (Cragun et al., 2015). 
Chapter two was a review manuscript and had the research question:  
a) what is the most recently available TNBC incidence rate and frequency among 
races/ethnicities? 
b) what are the risk factors associated with TNBC and do they differ among 
races/ethnicities? 
c) What are the knowledge gaps in the TNBC phenotypic research? 
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The research questions for the study that is reported in chapters three and four are 
a)  Is there a difference in age-adjusted and age-specific incidence rates for TNBC 
among races/ethnicities? 
b) Are there differences in phenotypic, demographic, and treatment features of 
TNBC tumors among races/ethnicities? 
c) What are the variables that are associated with TNBC compared to non-TNBC 
among the eight groups? 
d) Will there be higher/lesser odds for any race/ethnic group to develop TNBC 
compared to Non-Hispanic White women? 
e) What are the predictors for TNBC compared to Non-TNBC among the eight ethnic 
groups? 
Surveillance Epidemiology and End Results (SEER) program by the National Cancer 
Institute (NCI) is in operation since 1971 to provide information about cancer statistics on 
the U.S. population. There are 18 SEER registries across the country and has data for all 
cases diagnosed since 2000. SEER started with nine registries and since then has been 
adding states and regions of different states to represent the demographics of the U.S. 
population. The registries collect information about patient demographics, primary tumor 
site, specific cancer markers such as the hormone receptor status, cancer stage at 
diagnosis, first course of treatment, and patient survival (SEER Registries, n. d.). The 
education and poverty levels of the SEER population is very much alike to the U.S. 
population, but the percentage of foreign-born population is higher among the SEER 
population (17.9% versus 12.8%) (Population Characteristics, n. d.)  
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Data Collection by SEER 
 Cancer-related data are sent from sources such as hospital registries, pathology 
laboratories, and physician offices to the SEER Program’s central cancer registry. The 
information that is sent includes patient demographics, tumor identification, treatment 
and outcome. Each patient and tumor is given a unique identifier and is a combination of 
SEER participant number, patient ID number and record Number. Each registry gives a 
unique eight-digit number for each patient that will be called the patient ID number. The 
record number is the sequential number of the records that are received on a single patient 
and is automatically generated by the computer. (SEER Research Data Record 
Description, 2017).  
 SEER collects and codes information about neoplasm that include but not limited to 
date of diagnosis, whether situ or malignant, the number of the tumor among the rest of 
the primaries, primary site, side of the body where the tumor originated, and diagnostic 
confirmation (via histology, non-microscopically, or unknown in case of death certificate 
alone). SEER uses International Classification of Diseases for Oncology, 3rd edition to 
specify histology of the tumor, behavior code that corresponds to the malignant potential 
of the tumor (0 for benign and 3 for malignant), grade differentiation (grades I to IV), 
stage of cancer, first course of therapy, treatment status to note if patient received 
treatment or not, surgery at primary site or at other sites including lymph nodes, or the 
reason if a surgery was not performed, information about other treatments are also 
entered using SEER codes, and date of last follow-up or death. Annually SEER requires 
all its registries to do a vital status check to indicate if the individual is alive or dead 
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(SEER Research Data Record Description, 2017). SEER does not collect information 
such as nativity status (foreign-born or U.S. born), hormone therapy information as a 
treatment method, genetic mutation test results. Chemotherapy detail on patients is not 
efficiently categorized; SEER has grouped “unknown” along with “no”. Hence caution 
needs to be exercised to avoid interpretation biases.   
Data quality is maintained by quality control activities and Data Management System 
(SEER*DMS). The SEER*DMS supports all core cancer registry functions such as data 
importing, editing, linkage, consolidation, and reporting. Since SEER has a centralized 
system design, data quality and consistency is improved, efficiency increased as well as 
increased sharing of knowledge and experience among registries (Quality Improvement, 
n. d.).  
Accessing SEER Data  
 To access SEER data, a Data-Use agreement form was signed (Appendix B). The 
form for request is found at http://seer.cancer.gov/data/request.html. SEER registry data 
was available free of charge. Permission to conduct the study was obtained from Clemson 
University’s Institutional Review Board (Appendix C). The exempt review process was 
undertaken as there were no patient identification details in SEER data. The required 
forms were submitted and approved for the study. All the researchers were up-to-date on 
Collaborative Institutional Training Initiative. Data collection and analysis was initiated 
after obtaining IRB approval and gaining SEER access. 
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Data Analysis 
 Special software download was necessary to access and analyze the data. SEER*Stat 
was an available software to do statistical analysis and was directly downloaded from 
internet. Software Package for Social Sciences (SPSS) version 24.0 was used to perform 
statistical analysis for this study. A Binary logistic regression analysis was performed in 
Chapter four when there is one categorical outcome variable and two or more predictor 
variables which could be only continuous variables or both categorical and continuous 
variables. Chi-square statistic was performed in Chapters three and four to analyze data 
related to a research question that involved one categorical outcome and one categorical 
predictor variable (Field, 2013). Statistical significance was declared when p value was 
less than or equal to 0.05. SPSS statistical software version 24 was used for research 
described in chapters three and four, whereas SEER*Stat software was used for a part of 
the study described in chapter three alone. 
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CHAPTER 2 
TRIPLE NEGATIVE BREAST CANCER (TNBC) PHENOTYPIC AND 
GENOTYPIC TRAITS AMONG WOMEN OF COLOR IN THE UNITED 
STATES: A REVIEW 
Introduction 
Triple Negative Breast Cancer (TNBC) is a type of breast malignancy with a lack 
of tumor expression for the Estrogen Receptor (ER-), Progesterone Receptor (PR-), and 
Human Epidermal growth factor Receptor (HER-2-). See Table 2.1 for St. Gallen 2011 
consensus for clinico-pathologic definition of intrinsic breast cancer sub-types 
(Goldhirsch et al., 2011). TNBC is treated by breast-conserving surgery (lumpectomy), 
mastectomy, radiotherapy, neoadjuvant treatment, and adjuvant systemic therapy (Wabha 
& El-Hadaad, 2015). In the study by Lian et al (2014) TNBC patients compared to 
Non-TNBC patients had 50% increased risk for all-cause mortality and even after 
covariate adjustment TNBC was significantly (p < 0.05) associated with non-Breast 
Cancer mortality due to circulatory system diseases, other cancers or causes (HR = 2.15) 
and Breast Cancer-mortality (HR = 1.42). The purpose of the review is to, for the first 
time, provide the available TNBC incidence and frequency data for different ethnicities, 
describe the various phenotypes of TNBC in women of color (African-American women, 
Hispanic, Asian sub-groups) and to compare/contrast the risk factors among them. 
Second, to determine if there are a variety of mutations, especially for BRCA1 positive 
and or triple negative phenotype in these groups. Finally, to determine what similarities 
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or differences among races/ethnicties affect early detection, prevention and treatment for 
women.  
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Table 2.1 
Surrogate Definitions for Intrinsic Breast Cancer subtypes  
Intrinsic subtype Clinico-pathologic definition 
Luminal A Luminal A; ER and /or PR+ HER2- 
Ki-67 low (<14%) 
Luminal B Luminal B (HER2-); ER and /or PR+ HER2- Ki-67 high 
Luminal B (HER2+); ER and /or PR+ HER2 overexpressed;  
  any Ki-67 
Erb-B2 
overexpression 
HER2 positive (non-luminal) 
ER and PR absent; HER2 overexpressed or amplified 
Basal-like Triple Negative (ductal),  
ER and PR absent HER2 negative 
Note. Definitions for terms. Adapted from “Strategies for subtypes--dealing with the 
diversity of breast cancer: Highlights of the St. Gallen international expert consensus on 
the primary therapy of early breast cancer 2011,” by A. Goldhirsch, W.C. Wood, A.S. 
Coates, R.D. Gelber, B. Thurlimann, H.J. Senn, & Panel members, 2011, Annals of 
Oncology: Official Journal of the European Society for Medical Oncology, 22(8), p. 
1736-1747.  
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Racial/ethnic differences for TNBC has been documented for cancer recurrences 
(Kanaan et al. 2014), overall survival (Banegas et al., 2014; Bauer, Brown, Cress, Parise, 
& Caggiano, 2007; Lin et al., 2012; Tao, Gomez, Keegan, Kurian, & Clarke, 2015), and 
mortality (Lund et al., 2008; Matt, Mozayen, Gress, & Tirona, 2015; Parise & Caggiano, 
2016). TNBC women were twice more likely to die from the disease compared to all 
other Breast Cancer/BC subtypes (p < 0.0001) (Matt et al., 2015). Tao et al. (2015), used 
California Cancer Registry data and showed that African American women with Stage III 
TNBC had higher hazards of BC death compared to Whites (n=103,498) and this is after 
adjusting for tumor characteristics, first course of treatment, neighborhood socio 
economic status and insurance status. Also, worst breast cancer survival was found for 
TNBC tumors diagnosed between Stages II and IV (Tao et al.). 
Hispanic women with TNBC data recorded in California Cancer Registry were 
reported to have poorer survival compared to women with HR+/HER2- tumors (Banegas 
et al., 2014). In this study, when stratified by socio economic status, Hispanic women in 
the lower quintile had HR for breast cancer-specific mortality higher than women from 
the highest quintile (HR = 1.76 versus 1.38 respectively) (Banegas et al.). Parise and 
Caggiano (2016), identified TNBC mortality for combined Asian/Pacific Islander (API) 
was significantly lower compared to other Breast cancer sub-types (HR, 0.84; 95%CI, 
0.74-0.94, p < 0.049). Individual ethnicity risks were not published as they were 
non-significant (p > 0.05) (Parise & Caggiano, 2016).  
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Methodology 
A systematic synthesis of literature was completed on original research articles 
published from January 2007 to February 2017 using the search engines PubMed, 
CINAHL, and Web of Science Search terms included triple negative breast cancer, 
Caucasians, African Americans, Hispanic Americans, Asian Indians, TNBC, BRCA 
mutations. The search retrieved 900 articles that requested studies conducted in the 
United States and published in English. Duplicates, reviews, commentaries, and studies 
conducted in countries other than the United States were excluded. Next, reading through 
the abstracts, studies that described tumor genetic profile, drug studies, animal model 
studies, tumor expression studies, somatic BRCA mutations and studies on survival 
outcomes were excluded. The final selection for review was 85 articles. All articles were 
carefully reviewed for significant and non-significant data published on incidence, 
frequency of TNBC, risk factors, phenotype and genotype of TNBC, and similarities 
among early detection, prevention, as well as treatment. The tumor sub-types mentioned 
in this review reference the exact terminology used by authors of the individual articles. 
Similarly, terminology for race/ethnicity are used exactly as stated in the article, example: 
Black, African American, or Non-Hispanic Black This dissertation followed the U.S. 
Census Bureau definitions for Non-Hispanic White, Non-Hispanic Black. Non-Hispanic 
white are white population who are not of Hispanic origin (U. S. Census Bureau, 1999). 
Similarly, Non-Hispanic Black are Black population who are of not Hispanic origin. 
Refer to Table 2.2 for review of terminology. 
 
25 
 
Table 2.2 
 
Review of Terminology  
 
Terms Definitions 
Age-adjusted 
incidence rate 
A statistical method allowing comparisons of populations that 
considers age-distribution differences between populations 
Age-specific 
incidence rate 
The rate of incidence of a specific age group, calculated per 
100,000 people 
Odds Ratio A measure of the odds of an event happening in one group 
compared to the odds of the same event happening in another 
group 
Hazard Ratio A measure of how often a event happens in one group compared 
to how often it happens in another group, over time.  
Tumor Stage Stage provides a measure of disease progression, detailing the 
degree to which the cancer has advanced. 
Tumor Grade A description of a tumor based on how abnormal the cancer 
cells and tissue look under a microscope and how quickly the 
cancer cells are likely to grow and spread. 
Chemotherapy Treatment that uses drugs to stop the growth of cancer cells, 
either by killing the cells or by stopping them from dividing 
Radiotherapy The use of high-energy radiation from X-rays, gamma rays, 
neutrons, protons, and other sources to kill cancer cells and 
shrink tumors. 
Hormone 
therapy 
Treatment that adds, blocks, or removes hormones. 
Note. Review of Terminology (n. d.). National Cancer Institute Dictionary of Cancer 
Terms. Retrieved from 
https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45110  
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Incidence of Triple Negative Breast Cancer 
The most recently reported age-adjusted incidence rate for TNBC, published by 
Kohler et al. (2015), included data from the North American Association of Central 
Cancer Registries (NAACCR) for patients with hormone (estrogen and progesterone) 
receptors and HER2 receptor information. The overall age-adjusted incidence rate for 
TNBC was 15.5 per 100,000 person-years. When categorized by race/ethnicties the rate 
was highest among Non-Hispanic (NH) Black followed by NH White, Hispanics and NH 
Asian/Pacific Islander (27.2, 14.4, 11.8, 10.3 per 100,000 person-years respectively) for 
the year 2011 (Kohler et al., 2015). The National Cancer Database’ (Plasilova et al., 2016) 
described female invasive breast cancers (n=295,801) diagnosed between 2010-2011, and 
showed TNBC ranked second in frequency after HR+ HER2- subtype. Similar to results 
by Llanos et al. (2015) for New Jersey women diagnosed from 2006-2012, Lund et al. 
(2009) found TNBC was ranked second in frequency after the HR+/HER2- breast cancer 
subtype (98.9 versus 27.8 per 100,000) (Lund et al.,2009) in women diagnosed between 
the years 2003 and 2004 in the Atlanta Surveillance Epidemiology End Results (SEER) 
and Georgia Comprehensive Cancer registries. However, these results were from 
predominantly White and Black populations with only 3.3% from other race/ethnicities 
(Lund et al., 2009).  
The NH Black group of women ranked first in TNBC frequency followed by 
Hispanic, NH White, and NH Asian/Pacific Islander groups (23.7%, 14.8%, 11.4%, 
11.2%, respectively) (Plasilova et al., 2016). Comparing NH Black and NH white women, 
the NH Black women had an age-adjusted rate of 36.3, almost twice the rate compared to 
27 
 
the age-adjusted rate of 19.4 in NH White women, (Lund et al., 2009). Similar results 
published by Phipps et al. (2011) found TNBC in NH White women as 2.44 cancers per 
10,000 person-years compared to 4.57 cancers per 10,000 person-years among African 
American women. This study used cases diagnosed between 1993-1998 and was 
restricted to women aged 50 to 79 years (Phipps et al., 2011).  
Incidence differences between TNBC and Non-TNBC tumors among ethnic 
minorities compared to White women have been reported by a variety of researchers.  
See Table 2.3 Next to Black women (23.7%), Asian Indian (15.6%), American 
Indian/Eskimo (14.6%), Chinese (11.9%), Vietnamese (11.5%), Japanese (11.3%), and 
Filipino (8.9%) rank highest in TNBC tumor frequency (Plasilova et al., 2016). However, 
the incidences in Korean, Chinese, Vietnamese, and Japanese women were 
non-significant (Plasilova et al.).  
Most recently Plasilova et al. reported age-specific TNBC frequency in the age group 
< 30 years, was highest with a frequency of 23.3% with the remaining groups with 10 
year ranges from 30 years to >70 years which revealed a declining trend for TNBC from 
21.1% to 10%. Finally, HR+ HER2- had an inverse trend across the age groups. TNBC 
age-specific incidence rate using data from SEER registries showed NH Black women to 
be highest in TNBC frequency across all age-groups with the peak among those 65 to 69 
years compared to women of other races (Howlader et al. 2014). The TNBC age-specific 
incidence rate for NH Blacks for the age-group 65 to 69 years was 69.5 compared to 36.8 
among NH Whites, 28.8 among Hispanics and 23.6 among NH Asian Pacific Islander of 
the same age, all rates per 100,000 (Howlader et al., 2014). Similar results published by 
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Amirikia et al. (2011) used information from the California Cancer Registry (n=375,761). 
Clarke et al. (2012) found that Black women have an elevated TNBC age specific 
incidence rate compared to White, Hispanics, and Asian (study sample, n=9,737 TNBC 
cases) and reported the TNBC incidence rate ratios by comparing relative risk of an 
ethnic group to a specified reference group (Clarke et al.). For Black versus White 
women, aged 35 years and above, the TNBC Incidence rate ratio was significantly greater 
than 1.0 (p < 0.05) (Clarke et al.). For Asian versus White women, the TNBC incidence 
rate ratio for women more than 35 years of age, was found to be less than 1.0; for 
Hispanic vs, white TNBC women more than 55 years, incidence rate ratio less than 1.0 (p 
< 0.05) (Clarke et al.).  
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Table 2.3 
Journal Articles Published on TNBC Incidence 
Authors/Year Data Source, Years Sample Population 
Plasilova et al., 2016 National Cancer Database 
(NCDB), 2010-2011 
NH White, NH Black, NH 
API, Hispanic, Other 
(n=295,801) 
Llanos et al., 2015 Women in New Jersey 
(Breast Cancer Treatment 
Disparity Study), 2006-12 
African American, White 
(n=629) 
Kohler et al., 2015 North American 
Association of Central 
Cancer Registries 
(NAACCR), 2011 
Non-Hispanic White (NH), 
NH Black, Hispanic, NH 
Asian/Pacific Islander 
(API) (n*) 
Howlader et al., 2014 17 Registries from SEER, 
2010 
NH White, NH Black, NH 
API, Hispanic (n=57,843) 
Clarke et al., 2012 California Cancer Registry 
(CCR) 2006-2009 
White, Black, Hispanic, 
Asian (n=91,908) 
Phipps et al., 2011 Women’s Health 
Initiative, 1993-1998 
NH White, Hispanic or 
Latina, African American, 
Other (n=155,723) 
Amirikia et al., 2011 California Cancer 
Registry, 1988-2006 
NH White, NH Black, 
Hispanic (n=375,761) 
Lund et al., 2009  
 
Metropolitan Atlanta 
SEER Registry (MASR) 
and Georgia 
Comprehensive Cancer 
Registry (GCCR), 2003-04 
White and Black women 
(n=1,842) 
Note. n*- Population used in calculation for the year 2011 was not provided. 
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Phenotype of Triple Negative Breast Cancer 
Tumor Histology 
Seven studies report that TNBC’s histology is often presented as ductal carcinoma 
(Plasilova et al., 2016; Llanos et al., 2015; Orucevic et al., 2015; Kanaan et al., 2014; 
Swede et al., 2011; Tawfik et al., 2010; Telli et al., 2011). These tumors are significantly 
less likely to be lobular or mixed compared to the ductal type (p = 0.001) (Rummel, 
Varner, Shriver, & Ellsworth, 2013; Swede et al.) and a retrospective study with 700 
cases reporting a significant finding of only 2.4% lobular versus 89% ductal cancers (p = 
0.003) (Tawfik et al.), and 94% ductal carcinoma (Rummel et al., 2013). Llanos et al. 
(2015), reported 91.2% to be invasive ductal and significantly different from other 
subtypes that ranged in frequency from 80.2% to 85.7% (p = 0.0006). Swede et al. (2011) 
used the Connecticut Tumor Registry of White and Black women diagnosed 2000-2003, 
to report that TNBC was found to be 3.37 times more likely to be medullary type 
(non-significant, p = 0.06) compared to all other BC-subtypes. There are also other 
histologic sub-types reported for TNBC from adenoid cystic to tubular carcinoma (78.2% 
to 0.3%), and for few of those types there was no significant difference with other BC 
subtypes (Plasilova et al.). 
Tumor Stage 
Studies report TNBC to be staged by the American Joint Committee on Cancer 
(AJCC) at stage II and above; a finding reported by eight studies (Parise & Caggiano, 
2017; Bauer et al., 2007; Brown, Tsodikov, Bauer, Parise, & Caggiano, 2008; Lin et al., 
2012; Llanos et al., 2015; Rizzo et al., 2009; Rummel et al., 2013; Lund et al., 2010). 
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There was a high frequency of stages II, III, and IV noted among TNBC compared to 
Luminal type A cancers (65.8% versus 46.8% respectively); 17.7% of TNBC cases were 
stages 3 and above versus 11.2% Luminal type A (Parise & Caggiano, 2017), 53.8% of 
the TNBC cases were stage II and above, significantly different from 38.8% among 
Luminal A cancers (p = 0.0087) (Llanos et al., 2015) and 60% of TNBC cases are greater 
than stage II at presentation in a Clinical Breast Care Project (n=190 TNBC cases) 
(Rummel et al., 2013). A retrospective chart review of women diagnosed from 2000-2006 
with Stage III breast cancer in a single inner-city cancer center revealed TNBC tumors in 
high proportions (29%) (Rizzo et al., 2009). TNBC tumors had significantly (p = .049) 
higher frequencies in regional and distant tumors compared to patients with local disease 
(25.1% and 27.8% versus 18.3%, respectively) (Swede et al., 2011). Zaky et al. (2011) 
reported non-significant (p = 0.728) differences between TNBC and non-TNBC tumors 
for AJCC stages I-III and non-significant (p > 0.05) higher odds were reported for TNBC 
tumors of stages III and IV compared to lower stages (Lund et al., 2010; Lund et al., 2008; 
Trivers et al., 2009; Telli et al., 2011). 
Tumor Size 
Eight studies report findings of TNBC tumor size >2 cms (Plasilova et al., 2016; 
Parise & Caggiano, 2017; Llanos et al., 2015; Santebennur et al., 2008; Sineshaw et al., 
2014; Lund et al., 2010; Kanaan et al., 2014; Banegas et al., 2014). Findings from Parise 
and Caggiano (2017) showed that 55.6% of TNBC tumors were >2 cms at presentation 
versus 34.5% among Luminal A subtype. Like findings noted by Lund et al., 2009, 
Sineshaw et al. (2014) found that TNBC significantly (p < 0.0001) ranked second in 
32 
 
frequency to HR+ HER2- for tumors >5 cms in diameter. Mean tumor size reported by 
Plasilova et al. (2016) for TNBC was significantly (p < 0.001) higher than HR+/HER2- 
(2.78 cms versus 2.04 cms, respectively). Only 16.5% of the TNBC cases were <1 cm 
compared to 40.5% in Luminal A cancers (Llanos et al.). Compared to estrogen 
Receptor+ tumors, TNBC tumors are significantly (p < 0.05) >2 cms in mean diameter at 
presentation (Kanaan et al., 2014). 
Three studies (Brown et al., 2008; Bauer et al., 2007; Tawfik et al., 2014) reported 
median size as 2 cms or above for TNBC, significantly (p < 0.001), different from 1.7 
cms in other BC subtypes. Two studies (Orucevic et al., 2015; Zaky et al., 2011) reported 
no statistically significant differences (p > 0.05, p = 0.06 respectively). The 
non-significant findings could be due to the differences in sampling, women from one 
group of race/ethnic origin (Orucevic et al., 2015) and a relatively small sample size from 
a geographic location (Zaky et al., 2011). 
Tumor Grade 
Tumor grade is the description of how abnormal the tumor cells appear under a 
microscope and they indicate how quickly a tumor can grow and spread. It is classified as 
Grade I (well differentiated), Grade II (Moderately differentiated), Grade III (Poorly 
differentiated), and Grade IV (Undifferentiated). It is used by doctors to determine a 
patient’s prognosis and to develop a treatment plan (AJCC Tumor Grade, 2010). TNBC 
frequently are high grade tumors with a majority classified as grade II and above. Fifteen 
studies reported a significant association (p < 0.05) of high grade tumors with TNBC 
(Plasilova et al., 2016; Parise & Caggiano, 2017; Sineshaw et al., 2014; Llanos et al., 
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2015; Tawfik et al., 2014 Orucevic et al., 2015; Morris et al., 2007; Lund et al., 2009 
Lund et al., 2008; Banegas et al., 2014; Zaky et al., 2011; Rummel et al., 2013; Brown et 
al., 2008; Bauer et al., 2007; Kanaan et al., 2014) and that patients with TNBC tumors 
consistently presented with higher grade tumors compared to other breast sub-types or 
Luminal type A cancer depending on the study methodology. The TNBC frequency for 
grade III and higher tumors ranged from 64.7% to 100% in the above referenced research 
articles.  
Odds Ratio for a TNBC to be higher grade ranged from 9.7 times compared to BC 
sub-types (Llanos et al., 2015) to 17 times compared to Luminal A cancer (Sineshaw et 
al., 2014). A few other studies reported TNBC to have higher odds for higher grade 
tumors (Kanaan et al., 2014; Orucevic et al., 2015; Telli et al., 2011). Howlader et al. 
(2014) found TNBC patients were 20 times more likely to present with high grade tumors 
after controlling for race, age and stage of disease. Irrespective of TNM staging, TNBC 
tumors presented with high histologic grade and high Nottingham score compared to 
Non-Triple negative phenotype (Orucevic et al., 2015). Also, non-significant higher odds 
of 29.5 (95% CI 26.4-33.0) were reported for grade III tumors (versus grade I) associated 
with TNBC (Telli et al., 2011).  
Lymph Node Invasion 
Four studies reported findings for TNBC related to lymph node invasion (Plasilova et 
al., 2016; Banegas et al., 2014; Llanos et al., 2015; Khan et al., 2009). Plasilova et al. 
found a significant (p < 0.001) association between lymph node invasion (positive) and 
TNBC versus HR+HER2- tumors, reported as 25% of TNBC cases versus 19% among 
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HR+ HER2 -. Llanos et al. (2015) reported 19.8% of TNBC cases versus 18.1% of 
Luminal A cancers positive for lymphovascular invasion. Among Hispanic women with 
breast cancer, positive lymph node invasion was reported with significant (p < 0.05) odds 
ratio of 0.54 for TNBC compared to HR+/HER2- (Banegas et al., 2014). Similarly, Khan 
et al. (2009) reported a frequency of 51.4% positive for lymphnode invasion in a 
predominantly (~95%) Hispanic sample.  
TNBC tumors can also present with clinically metastatic disease (Plasilova et al., 
2016). Compared to Non-TNBC cases, TNBC cases showed significance (p = 0.010) for 
a high frequency of both local and distant metastasis (Zaky et al., 2011). Non-statistically 
significant differences were noted between African American and Caucasian women for 
local and distant metastatic disease (p = 0.450) (Zaky et al., 2011). Though not 
statistically different in this study, African American women had double the rate for local 
metastasis and triple the rate for distant metastasis compared to Caucasian women (p = 
0.450) (Zaky et al.). 
Are there differences in TNBC Phenotype Among Women of Color? 
Original research articles were reviewed to synthesize information published on 
differences in TNBC phenotypes among women of color. The race/ethnic origins 
included in the studies reviewed were NH White, NH Black, Hispanic and Asians. 
African American and Caucasian women 
Significant differences between African American and Caucasian women with 
TNBC were reported by six studies (Chen &Li, 2015; Tao, Gomez, Keegan, Kurian, & 
Clarke, 2015; Chu, Henderson, Ampil, & Li, 2012; Swede et al., 2011; Tawfik et al., 
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2014; Sullivan et al., 2014). Chen and Li (2015) reported African American and 
American Indian/Alaska Native women often present with stages II, III and IV compared 
to Stage I in NH White, a significant finding (p < 0.05). However, Filipinos and Pacific 
Islanders also often presented as Stages III/IV versus Stage I but a non-significant finding 
(p > 0.05) (Chen &Li). Chinese and Japanese often presented more often with Stage I 
compared to Stages II and above, also a non-significant finding (p > 0.05) (Chen &Li). 
Chen and Li also reported larger tumors in African American women compared to other 
ethnic groups. 
For TNBC ductal carcinomas, Black women had higher frequency compared to 
White women (34.8% versus 11.7%, p < 0.001) (Swede et al., 2011). Also, significant 
differences were found in the average size of a TNBC tumor between African 
American/AA and Caucasian American (3.23 cms versus 2.02 cms respectively, p < 
0.001) (Sullivan et al., 2014). Significant differences for grade (Chu et al., 2012), and for 
Lymphovascular invasion (44% in AA women versus 33% in Caucasian women 
respectively, p = 0.039) (Tawfik et al., 2014) has been reported.  
Non-significant (p > 0.05) ethnic differences were reported for multiple variables in 
five studies (Sullivan et al., 2014; Tawfik et al., 2014; Chu et al., 2012; Pacheco, Gao, 
Bumb, Ellis, & Ma, 2013; Sturtz, Melley, Mamula, Shriver, & Ellsworth, 2014). No 
significant differences were reported for tumor stage (Chu et al., 2012; Pacheco et al., 
2013), tumor size distribution (Chu et al., 2012; Tawfik et al., 2014), grade (Pacheco et 
al., 2013; Tawfik et al., 2014), lymph node invasion (Sturtz et al., 2014), and nodal 
distribution (Chu et al., 2012). A study concluded that racial differences for clinical 
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presentation (African American and Caucasian) were not observed among 493 TNBC 
cases and for TNBC outcome, such as disease free survival and overall survival (Pacheco 
et al., 2013). However, it needs to be emphasized that it was a retrospective single center 
study (n=493) and the cases were diagnosed between 2006 and 2010 when better 
treatment options (for disease outcomes) became available compared to the studies that 
used data from the 1990s (Pacheco et al., 2013).  
African American Women and Women from Other Ethnic Groups 
 When comparing African American women with women of other ethnicities, 
non-significant differences were observed. Among Black and Hispanic women TNBC 
tumors (compared to ER+ PR+ HER2- tumors) often present as 2- 4.9 cms in tumor size 
compared to tumor size 1-5 millimetres (OR = 1.47, 1.20 respectively), and along with 
these two groups, Asian Pacific Islanders have higher odds for tumor sizes more than 5 
cms (OR = 1.93, 1.63, 1.63 respectively), all non-significant findings (p > 0.05) (Parise & 
Caggiano, 2017). Similarly, for tumor grade, Black and White women have higher odds 
for poorly differentiated tumors (OR = 55.35, 47.42 respectively) compared to Luminal A 
subtype and Hispanic women along with Black women have higher odds for 
undifferentiated tumors (OR = 63.37, 56.19 respectively) (p > 0.05) (Parise & Caggiano, 
2017). 
Iqbal, Ginsburg, Rochon, Sun, & Narod (2015) reported non-significant (p > 0.05) 
ethnic differences among women diagnosed with TNBC tumors less than or equal to 
2cms diameter using 18 SEER registries (n=53,577). Black women had the highest 
proportion of 17.2% compared to 10.4% among South Asians (Asian Indian, Asian 
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Indian/Pakistani, or Pakistani), 10% among Hispanics, 8.8% for Chinese and 8.2% for 
Japanese, and 8% among Non-Hispanic White (Iqbal et al.). Non-significant differences 
reported between Black and White/other TNBC cases for histology (p = 0.969), stage (p 
= 0.061), grade (p = 0.382), number of nodes (p = 0.467) (Dawood et al., 2009).  
Hispanic women 
Among Hispanic women, TNBC women compared with HR+HER2- subtype, were 
approximately twelve times more likely to have a high tumor grade compared to low 
tumor grades (p < 0.05) (Banegas et al., 2014). The same study reported a significant 
association (p < 0.05) between tumor size and TNBC with approximately two-thirds of 
the cases having tumor sizes >2 cms and higher odds observed for those with >5 cms at 
diagnosis (OR = 1.59, 95% CI = 1.31-1.91) and between 2-5 cms (OR = 1.29, 95% CI 
=1.14-1.45) compared to <2 cms HR+HER2- tumors (Banegas et al., 2014).  
Genotype of Triple Negative Breast Cancer 
BRCA 1/2 Mutations 
Four studies done among TNBC cases reported prevalence of BRCA mutations 
(Lynce et al., 2015; Gonzalez-Angulo et al., 2011; Sharma et al., 2014; Rummel et al., 
2013). Lynce et al. (2015) reported 21.4% of TNBC cases (n=211, four in BRCA1 and 
two in BRCA2) to have deleterious mutations, in a breast cancer study sample with young 
Black women only. Another study (n=207) reported deleterious BRCA1 mutation 
prevalence of 11.1% and 4.3% for BRCA2 (Sharma et al., 2014). Gonzales-Angulo et al. 
(2011) reported an incidence of 15.6% for BRCA1 (including one somatic TNBC case) 
and 3.9% for BRCA2 mutations among 77 TNBC cases. Rummel et al. (2013) found a 
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frequency of 9% clinically important BRCA1 mutations. The same group compared 
BRCA1 mutation frequency based on significant risk factors and it was found that patients 
with BRCA1 mutation along with risk factors had higher frequency compared to those 
without significant risk factors (Rummel et al., 2013). For women aged < 60 years, 
BRCA1 frequency was 11.2-18.3% for those with risk factors versus 4.6% without risk 
factors; for women > 60 years of age, BRCA1 frequency 3.5%-7.7% with risk factors 
versus 2.3% without risk factors (Rummel et al., 2013). See Appendix D for research 
publication that address clinically important BRCA1 mutations (deleterious mutations) 
and ethnicity in detail. Risk factors were based off the Hereditary Breast and Ovarian 
Cancer Syndrome Testing criteria by the National Comprehensive Cancer Network 
(Rummel et al., 2013) and Appendix E for copyright permissions from Rummel et al., 
2013. 
BRCA mutations and TNBC. Studies reports significant higher proportion of 
TNBC cases among BRCA mutation carriers. Pal et al. (2015) reported a mutation among 
30% of TNBC cases compared to 7.1% of ER+ positive cases among women less than 50 
years of age. TNBC cases significantly approximately three times higher among BRCA 
carriers versus non-carriers (Pal et al., 2015). Eight studies assessed for BRCA1/2 
prevalence in relation to ethnicity (Greenup et al., 2013; Rummel et al., 2013; Rao et al., 
2011; Pal et al., 2015; Lagos-Jaramillo et al., 2011; Nahleh et al., 2015; Bayraktar et al., 
2015; Gonzalez-Angulo et al., 2011). Rummel et al. (2013) assessed for BRCA1/2 
mutations in their cohort of 182 women and reported 38% of their BRCA carriers were 
African-American and more than 85% of the BRCA carriers were diagnosed less than 60 
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years. Dean et al. (2015) reported two of the seven deleterious mutations in a Hispanic 
sample to be TNBC, a non-significant finding (29%). One of the seven reported was a 
newly described allele, 6005delT in BRCA 2 (Dean et al., 2015).  
BRCA mutations among races/ethnicities. Among Hispanic women with Mexican 
descent, 61% of BRCA mutation carriers compared to 28.6% among non-BRCA carriers 
were TNBC, p = 0.014 (Nahleh et al., 2015). Greenup et al. (2013) conducted a study 
among TNBC cases, who came for genetic counselling. They found that BRCA 
prevalence significantly differed between races and by age at diagnosis (Greenup et al., 
2013). Ashkenazi Jewish women had the highest percentage (50%), followed by 
Caucasian (33%), Asian/East Asian (29%), African American (21%), and 
Latina/Hispanic (20%) (Greenup et al., 2013). However, Gonzales-Angulo et al. (2011) 
report that significant differences in incidence of BRCA 1/2 mutation was not observed 
between Black, Hispanic, White and others. 
Pal et al. (2013) found a 6.5% prevalence for BRCA mutation among 
African-Americans with early onset breast cancer (n=46). Among Hispanics and 
Non-Hispanic Whites, BRCA1 mutation carriers were majorly TNBC (Lagos-Jaramillo et 
al., 2011). Similar findings reported by Nahleh et al. (2014) on Hispanic women with 
Mexico as country of origin. A majority, 85% of the BRCA1 carriers, presented with 
TNBC compared to 27% of non-BRCA1 carriers (p < 0.001) (Nahleh et al., 2015). The 
same study reported that none of the BRCA 2 carriers were TNBC compared to 37% 
among non-BRCA2 carriers (Nahleh et al., 2015). Rao et al. (2011) documented a 4% 
(n=50) incidence of BRCA mutation among Asian Indian American women who 
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presented with stages 0, I, and II and it is not stated if these women were TNBC or not. 
BRCA1 carriers were more likely to have TNBC than BRCA2 carriers, a non-significant 
finding reported by one study (Bayraktar et al., 2015).  
Among TNBC cases, BRCA carriers and women with wild-type BRCA1 was 
assessed for clinic-pathologic tumor characteristics (Gonzalez-Angulo et al., 2011; 
Rummel et al., 2013; Sullivan et al., 2014; Lagos-Jaramillo et al., 2011), ethnic 
differences were not noticed (Rummel et al., 2013), but BRCA1 mutation carriers were 
significantly younger in age (Rummel et al., 2013). Studies reported no significant 
differences in age at diagnosis (Lagos-Jaramillo et al., 2011), patient outcomes (disease 
free survival, recurrence, dead of disease, and dead of other causes frequency) (Rummel 
et al.; Sullivan et al., 2014), lymph node status (Rummel et al., 2013), histology 
(Gonzalez-Angulo et al., 2011; Lagos-Jaramillo et al.), tumor size (Rummel et al., 2013; 
Lagos-Jaramillo et al., 2011), nuclear grade (Gonzalez-Angulo et al.; Lagos-Jaramillo et 
al.) tumor stage (Rummel et al.; Sullivan et al., 2014; Gonzalez-Angulo et al.), tumor 
grade (Rummel et al.), and BMI (Lagos-Jaramillo et al.) between BRCA mutation 
carriers and wild-type TNBC cases.  
BRCA 1/2 mutation and age at diagnosis. Younger age at diagnosis is associated 
with BRCA mutations (Greenup et al., 2013; Nahleh et al., 2015; Sharma et al., 2014; 
Sullivan et al., 2014; Rummel et al., 2013; Lynce et al., 2015; Gonzalez-Angulo et al., 
2011). Women aged less than 50 years at diagnosis had a high prevalence of BRCA 1 
mutations compared to women between 51 and 60 years of age (27.6% vs 11.4%, p = 
0.0007) (Sharma et al., 2014). Nahleh et al. (2014) reported that a majority (72%) of 
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BRCA mutation carriers were less than 50 years of age when they presented with breast 
cancers. This was a non-significant (p = 0.638) finding. The Greenup study found 84% of 
women less than 40 years of age had a BRCA1 mutation and TNBC was significantly 
associated with age at diagnosis (Greenup et al., 2013). A declining trend was observed in 
the percentage of BRCA mutation positive cases for women age less than 40 years to 
women above 70 years (44% versus 17%, respectively) (Greenup et al., 2013).  
Studies consistently reported that when compared to sporadic cases, women with 
TNBC and BRCA mutation(s) are significantly younger at clinical presentation 
(average age), 45.8 years versus 54.8 years (Sullivan et al., 2014; Rummel et al., 2013), 
45 years versus 53 years (Gonzalez-Angulo et al., 2011), 43 years versus 51 years 
(Dean et al., 2015), 41.6 years versus 51.4 years (Lynce et al., 2015) and 40.2 versus 
55.7 years for BRCA1 (p < 0.0001) and non-significant difference (p = 0.14) with 
BRCA2 (Sharma et al., 2014).  
Other gene mutations and Variants of Uncertain Significance 
Mutations in other genes and Variants of Uncertain Significance (VUS) were 
reported by four studies. One study (n=103) reported that among African American 
women, 25% of those with deleterious mutations were TNBC and the four genes 
associated were CHEK2, PALB2, ATM, and PTEN while the remaining 50% were in the 
BRCA 1/2 genes (Churpek et al., 2015). Sharma et al. (2014) observed VUS only in 3.4% 
of the study participants. However, Rummel et al. (2013) documented cases with VUS in 
18% of study patients; Pal et al. (2013) reported VUS in 34.8% of the African American 
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study sample; and 2 cases with VUS reported by Churpek et al. (2015), one in BRCA1 
and another in BRCA2. 
Single Nucleotide Polymorphisms (SNPs) 
Three studies reported their findings on SNPs related to TNBC (Han et al., 2015; 
Haiman et al., 2011; Palmer et al., 2012). Palmer et al. (2012) reported two SNPs, 
rs10069690 in 5p13.33 (TERT gene) and rs8170 in 19p13.11 (TERT gene), to be 
significantly (p = 0.02, 0.04 respectively) associated with TNBC. Han et al. reported 
SNPs in 10q26/FGFR2 location (rs1219648) and 2q33/CASP8 (rs1045485) to be 
significantly (p < 0.05) associated with TNBC. Another SNP reported at the 
TERT-CLPTM1L locus on chromosome 5p15 (rs10069690) found to be significantly 
associated with TNBC (p = 1.1X10-9) (Haiman et al., 2011; Palmer et al., 2012) in 
women less than 50 years of age (Haiman et al., 2011). Palmer et al. further documented 
that rs10069690 and rs8170 had significantly (p = .008) higher risk for developing TNBC 
among African Americans only. Of note, the frequency of this allele is significantly [p = 
1.1 X 10 (-9)] higher in women with African ancestry compared to European ancestry 
and this highlights the role of genetic susceptibility in the incidence of TNBC (Haiman et 
al., 2011).  
Risk factors Similarities and Differences Among Ethnicities 
Information about risk factors was synthesized from studies that compared TNBC 
to Non-TNBC cases, most commonly HR+HER2- subtype, or with controls. 
Contradictory findings have been reported for many variables and each will be reviewed 
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in detail in the following sections. Refer to Table 2.4 for findings related to demographic 
risk factors from the literature.  
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Table 2.4 
Literature Citing Demographic Risk Factors for TNBC 
Demographic 
Risk Factors 
Studies with reported 
significant finding (p < 0.05) 
Studies with reported 
non-significant finding (p > 
0.05) 
Race/ethnicity Plasilova et al., 2016 
Tao et al., 2015 
Sineshaw et al., 2014 
Kanaan et al., 2014 
Boone et al., 2014 
Clarke et al., 2012 
Lin et al., 2012 
Telli et al., 2011 
Lund et al., 2010 
Kwan et al., 2009 
Stead et al., 2009 
Morris et al., 2007 
Zaky et al., 2011 
Swede et al., 2011 
Telli et al., 2011 
Hines et al., 2011 
Lagos-Jaramillo et al., 2011 
Trivers et al., 2009 
Lund et al., 2008 
Borderline significance  
Dolle et al., 2009 
Family History  Llanos et al., 2015 
Matt, Mozayen, Gress, & Tirona, 
2015 
Phipps et al., 2011 
Shinde et al., 2010 
Dolle et al., 2009 
Borderline significance  
Ambrosone et al., 2014 
Country of 
Origin 
Ambrosone et al., 2014 
Telli et al., 2011 
Banegas et al., 2014 
Age at 
Diagnosis 
Parise & Caggiano, 2017 
Plasilova et al., 2016 
Ambrosone et al., 2014 
Zaky et al., 2011 
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Table 2.4 (continued) 
Chen et al., 2016 
Orucevic et al., 2015 
Matt et al., 2015 
Llanos et al., 2015  
Banegas et al., 2014  
Ambrosone et al., 2014  
Sineshaw et al., 2014 
Tawfik et al., 2014 
Anders et al., 2011 
Shinde et al., 2010 
Santebennur et al., 2008  
Brown et al., 2008  
Kwan et al., 2009 
Lund et al., 2008 
Bauer et al., 2007 
 
Dolle et al., 2009 
Stead et al., 2009 
 
Socio-Economic 
Status 
Parise and Caggiano, 2017 
Llanos et al., 2015 
Banegas et al., 2014 
Chu et al., 2012 
Trivers et al., 2009 
Brown et al., 2008 
 
Parise and Caggiano, 2017 
Akinyemiju, Pisu, Waterbor, & 
Altekruse, 2015 
Howlader et al., 2014 
Zaky et al., 2011 
Telli et al., 2011 
Lund et al., 2010 
Education Llanos et al., 2015 Dolle et al., 2009 
Trivers et al., 2009 
Insurance Sineshaw et al., 2014 Llanos et al., 2015 
Banegas et al., 2014 
Telli et al., 2011 
Trivers et al., 2009 
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Country of origin 
Three studies reported associations between country of birth and TNBC. Ambrosone 
et al. (2014) compared TNBC cases with controls to show a significantly higher TNBC 
proportion for women whose country of origin was foreign-born., 72% of U.S. origin and 
19% of Caribbean origin were TNBC vs 81% were U.S.-born women and only 14% were 
for Caribbean origin in controls, p = 0.04. Bangeas et al. (2014) used data on Hispanic 
female residents diagnosed between 2005-2010 from CCR and reported 46.8% of TNBC 
women to be U.S.-born and 53.2% to be foreign-born. Additionally, the same group 
reported non-significant odds (p = 0.97) for TNBC among foreign-born versus U.S.-born 
women (Banegas et al., 2014). Telli et al. (2011) investigated association of TNBC with 
nativity (foreign born versus U.S.-born) and documented significant differences in 
subtype distribution among Asian women (Chinese, Japanese, Filipina, Vietnamese, 
Korean, South Asian, East Asian, and others) (p < 0.0001). Of all U.S. -born women in 
the study sample (n=8140), 11% had TNBC and 12% of the Foreign-born had TNBC 
(Telli et al., 2011). 
Race/Ethnicity 
More than thirty studies have reported associations between race/ethnicity and TNBC. 
Among TNBC cases, Parise and Caggiano (2017) reported White had the highest 
frequency of 57.1%, followed by Hispanics 21.1%, Blacks 11.7%, and Asian/Pacific 
Islander 10.2%. Kurian, Fish, Shema, & Clarke (2010) projected a life-time risk to 
develop TNBC for women of ethnicities in the following order: White, Black, Hispanic, 
and Asian with the assumption that the women in the study were cancer free at age 40. 
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Black women had the highest probability of developing TNBC followed by Whites, 
Hispanics and the least was for Asian/Pacific Islanders (Kurian et al., 2010).  
Black or African American women. Black women have the highest frequency of 
TNBC compared to other races (Ricks‐Santi & McDonald, 2016; Llanos et al., 2015; 
Chen et al., 2016; Chen &Li, 2015; Tao et al., 2015; Matt et al., 2015; Rana, 2009; Lund 
et al., 2008; Santebennur et al., 2008; Kwan et al., 2009; Sineshaw et al., 2014; Lund et 
al., 2009; Cui et al., 2014; Loo et al., 2011; Phipps et al., 2011; Sparano et al., 2012; Lin 
et al., 2012; Sturtz et al., 2014; Bauer et al., 2007; Iqbal et al., 2015; Shinde et al., 2010; 
Wright et al., 2012; Morris et al., 2007; Brown et al., 2008; Stead et al., 2009). Several 
studies show Black women lead with the highest frequency for TNBC followed by 
Hispanics and White (Parise & Caggiano, 2013; Howlader et al., 2014). Other studies 
found African American women compared to Caucasians to have significant higher odds 
for TNBC (Sineshaw et al., 2014; Lin et al., 2012; Kwan et al., 2009) and the frequency 
to be twice as high compared to White patients (Tao et al., 2015; Lund et al., 2010; 
Morris et al., 2007), to be three times more likely to develop TNBC (both p < 0.0001) 
(Stead et al., 2009) and to have significantly higher rate of TNBC at all ages, p < 0.05 
(Clarke et al., 2012). Tao et al. (2015) showed African-American women, when 
compared to White women, with Stage III TNBC had a 37% risk of breast cancer death 
(Tao et al., 2015). When TNBC was compared to ER positive tumors, African American 
women had a significantly higher rate of cancer recurrence (60% versus 20%, p < 0.05) 
along with significant lower rate of survival (47% versus 87%, p < 0.05) (Kanaan et al., 
2014). Non-significant (p > 0.05) findings were reported by few studies (Zaky et al., 2011 
48 
 
Lund et al., 2008; Swede et al., 2011; Trivers et al., 2009). Compared to Non-African 
American women or White women, African American/Black women had a three-fold 
prevalence for TNBC (Lund et al., 2008), three times more likely to develop TNBC 
tumors (multivariate OR =2.93) (Swede et al.), and almost three times more likely to 
develop TNBC versus the Luminal Type A subtype (Trivers et al.).  
Hispanic Women. TNBC is the second most common BC subtype among Hispanics, 
following HR+HER2- subtype, with a frequency of 15.6%, a California Cancer Registry 
dataset study (n=16,380) (Banegas et al., 2014) and 23.9% (n=309) in an affiliated county 
hospital study (Khan et al., 2009). Hispanics when compared to NH Whites were 17% 
more likely to have TNBC versus HR+/HER2- subtype (Sineshaw et al., 2014). Parise 
and Caggiano (2017) reported higher odds for TNBC among Hispanic women aged 50-59 
years when compared to women of the same age from Black and Asian Pacific Islander 
ethnicities. Compared to NH White women, Hispanic women had statistically significant 
differences in frequency of TNBC (16.4% versus 5.9% respectively, =0.0005) (Boone et 
al., 2014). There was a statistically significant (p < 0.001) higher proportion of African 
American and Hispanic women with TNBC compared to other BC-subtypes, but not with 
API women (Bauer et al., 2007). Other studies reported Hispanics to have non-significant 
(p > 0.05) higher proportion of TNBC compared to NH White (Lagos-Jaramillo et al., 
2011; Hines et al., 2011). 
Asians or Asian/Pacific Islander Women. Multiple studies report TNBC cases 
among sub-ethnicities in the Asian population (Parise & Caggiano, 2014; Parise & 
Caggiano, 2016; Telli et al., 2011 Plasilova et al., 2016; Brown et al., 2008; Lin et al., 
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2012; Bauer et al., 2007). Parise and Caggiano (2016) used CCR data to investigate the 
differences in TNBC frequency among White and Asian subgroups with a reported 
frequency to be highest among the Indian subcontinent populations (Asian Indian, 
Pakistani, Bangladeshi, Nepalese, Sikkimese, and Sri Lankan), followed by Korean, 
Southeast Asian (Vietnamese, Laotian, Hmong, Cambodian, Thai, and Burmese), and 
Whites (17.4%, 15.6%, 12% and 11.4% respectively). Pacific Islander had 10.9% 
followed by Chinese (10.6%), Japanese (10%) and the least among Filipino women 
(8.9%) (Parise & Caggiano, 2016). See Appendix F for email confirmation of a journal 
article submission on breast cancer incidence among Asian Indian American women in 
the United States versus women in India. 
Plasilova et al. (2016) analysed cases from the National Cancer Database targeting 
cancers reported 2010-2011. Compared to White women, Black, American 
Indian/Eskimo, and Asian Indians had significantly (p < 0.001, 0.008, 0.003 respectively) 
higher TNBC incidence and Filipino had significantly (p = 0.001) lower incidence 
(Plasilova et al.). Compared with other ethnic women from the API group, women from 
the Indian continent had 25% more likelihood to develop TNBC, while Chinese and 
Filipino women were less likely (20% and 35%, respectively) (Parise & Caggiano, 2014). 
When API women were compared to White women there was a lesser probability to 
develop TNBC, but when API women were categorized and then analysed, Blacks had 
the highest frequency (24.9%) followed by women from Indian Continent (16.5%), 
Hispanics (16.2%), American Indian (14.9%), Korean women (14.7%), South East Asian 
(12%), Pacific Islander (10.6%), Chinese (10.4%), Japanese (10.1%), and Filipino (9.6%) 
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(Parise & Caggiano, 2014). The Indian continent women included Asian Indian, Pakistani, 
Bangladeshi, Nepalese, Sikkimese and Sri Lankan (Parise & Caggiano, 2014).  
TNBC frequency was 21% among the Asian Indian American women population 
with stages 0, I, and II cancers (n= 50) (Rao et al., 2011). When NH White women are 
compared with the Asian for the risk of developing TNBC, non-significantly (p > 0.05) 
high odds ratios were found for the South-Asian women (OR = 1.3) followed by Korean 
(OR = 1.2). A decreased risk was identified for Chinese (OR = 0.8) and Filipina (OR = 
0.7) (Telli et al., 2011). This study used the data from California Cancer Registry (n=89 
009) and showed TNBC frequency among all breast cancers for each Asian group as: 18% 
for South Asian, 15% for Korean, 14% for Vietnamese, 11% for Chinese, 10% for 
Filipina, 11% for Japanese compared to 12% for NH White. All groups were significantly 
(p < 0.0001) different from NH White except Japanese (Telli et al., 2011). 
Of all TNBC cases in the study sample, 76% were Caucasians, 13% were African 
American, 7% were Hispanics, and 3% Asian Pacific Islander (Lin et al., 2012). Two 
studies using data from California Cancer Registry compared TNBC to other cancers and 
reported an overall TNBC frequency to be high among NH White women, then Hispanics 
and NH Black, (Bauer et al., 2007; Brown et al., 2008). Frequencies of 62.2% for NH 
White, 18.6% for Hispanics, 10% for NH Black, 8.4% for API and 0.8% for others were 
also reported (Bauer et al., 2007). Borderline significance (p = 0.05) between TNBC 
versus non-TNBC and race was reported by Dolle et al. (2009).  
 
 
51 
 
Family History 
Bethea et al. (2016) reported association of TNBC with family history of breast 
cancer (OR = 1.72 versus 1.67 for ER-) and for an African American woman who has a 
first degree relative with cervical cancer to have TNBC (OR = 3.04). The same study also 
reported higher odds for TNBC with family history of ovarian cancer (OR = 1.53) 
(Bethea et al., 2016). Six studies reported family history to be not significantly (p > 0.05) 
associated with TNBC (Llanos et al., 2015; Matt, Mozayen, Gress, & Tirona, 2015; 
Phipps et al., 2011; Rana, 2009; Shinde et al., 2010; Dolle et al., 2009) and only one 
study reported borderline significance, with 18% of cases with positive family history, p 
= 0.05 (Ambrosone et al., 2014). Family history as a risk is reported by five studies along 
with BRCA mutation (Rummel et al., 2013; Lynce et al., 2015; Sharma et al., 2014; 
Churpek et al., 2015; Gonzalez-Angulo et al., 2011). Lynce et al. (2015) reported a 
significant family history in 83.3% of TNBC mutation carriers versus 47.1% among 
TNBC non-carriers. Rummel et al. (2013) in their sample of 182, reported 25% of TNBC 
cases to have family history of breast and/or ovarian cancer. A study reported BRCA 
mutation prevalence as 31.6% for women with TNBC and significant family history/SFH 
when compared to 6.1% for TNBC women without SFH (Sharma et al., 2014). SFH is 
when there is a positive history for a breast cancer less than 50 years of age in the family 
or an ovarian cancer (Sharma et al., 2014). The study population of Sharma et al. (2014) 
includes the major race/ethnic groups however analysis was not carried out to see 
differences between races.  
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The proportion of deleterious mutations in familial TNBC cases was high compared 
to non-familial TNBC cases, but not a statistical significant finding (34% vs 14.9%, p = 
0.071) (Churpek et al., 2015). Another study reported 14 germline mutations among 
TNBC cases and only five of them had a first degree relative with breast and /or ovarian 
cancer, no further comparison details are provided (Gonzalez-Angulo et al., 2011). 
However, Dean et al. (2015), reported a non-significant difference in frequency of family 
history between BRCA carriers and non-carriers. 
Age at Diagnosis 
TNBC tumors occur primarily at younger ages with significant findings (p < 0.05) 
reported by seventeen studies (Parise & Caggiano, 2017; Plasilova et al., 2016; Matt et al., 
2015; Chen et al., 2016; Llanos et al., 2015; Orucevic et al., 2015; Banegas et al., 2014; 
Ambrosone et al., 2014; Bauer et al., 2007; Santebennur et al., 2008; Kwan et al., 2009; 
Sineshaw et al., 2014; Brown et al., 2008; Shinde et al., 2010; Anders et al., 2011; Lund 
et al., 2008; Tawfik et al., 2014). Women less than 40 years old had a high frequency of 
TNBC (19.7%) (Sineshaw et al., 2014). The mean age at diagnosis was lower among 
TNBC women compared to Luminal A subtype (56.7 years versus 60.6 years respectively) 
(Parise & Caggiano, 2017). Another study reported a mean age of 52 years for TNBC, 61 
years for HR+HER2- tumors and 56 years for HER2 overexpression tumors (p = 0.01) 
(Lund et al., 2008). When compared to non-TNBC cases the median age at diagnosis is 
significantly lower in TNBC cases: 51 versus 57 years respectively, p < 0.001 (Tawfik et 
al., 2014), 54 years vs 60 years, p < 0.001 (Bauer et al., 2007; Brown et al., 2008), 54.5 
years versus 59.3 years, p < 0.001 (mean age in Caucasian women only study) (Orucevic 
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et al., 2015). Only one study reported 56 years and it was not significantly different than 
Non-TNBC tumors (Maiti, Kundranda, Spiro, & Daw, 2010).  
Parise and Caggiano (2017) used data from the California Cancer Registry and 
showed that White and Hispanic women aged 30-39 years had higher odds (1.37 and 1.35 
respectively) for TNBC compared to women aged 50-59 years of same race/ethnic origin. 
Additionally, invasive breast cancer cases less than 50 years of age was double among 
TNBC compared to Luminal A subtype (Parise & Caggiano, 2017). One study identified 
a statistically significant (p = 0.0197) finding that three-fourths of TNBC sample was 
above the age of 45 years compared to other sub-types (Llanos et al., 2015). The average 
age at diagnosis for TNBC woman was 54 years and the age range was 29-91 years in a 
sample collected for the Clinical Breast Care Project (n=182) (Rummel et al., 2013) and 
the median age reported was 58 years compared to 60 years for HR+ and HER2+ cancers 
(Matt et al., 2015). TNBC is significantly associated with younger aged African 
American women (<40 years) when compared with non-African American older women 
(64% versus 29%, p = 0.03) (Anders et al., 2011). Despite the association of TNBC with 
younger age, the age-specific incidence rate is found to peak in the later years of life. A 
study using the SEER registry published that age-specific incidence rates for TNBC peak 
in the age groups 60-74 years (Amirikia et al., 2011).  
Parise and Caggiano (2017) in their large sample (TNBC, n= 19,283) noted that 50% 
of the Black women and 41% of the Hispanic who were less than 40 years had TNBC. 
Significant differences exist between ethnic groups (White, Black, API) for incidence rate 
ratios based on age at diagnosis, p < 0.05 (Clarke et al., 2012). Breast cancer incidence 
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rates for women less than 45 years of age at diagnosis were higher for Black women 
compared to White women (133.7 versus 129.2 per 100,000 woman-years respectively), 
and vice versa for women above 50 years of age (Clarke et al., 2012). Among TNBC 
cases, African American women had a significantly younger mean age at diagnosis 
compared to Caucasian women, 52.28 years versus 59.06 years respectively, p = 0.002 
(Sullivan et al., 2014). Banegas et al. (2014) reported significantly lesser risk for Hispanic 
women at ages 45-49 years compared to Hispanic women aged 50-54 years for TNBC 
risk, p < 0.05. For Non-Hispanic Black women, age-specific incidence rates for TNBC 
peak in the age group 65-69 years (Howlader et al., 2014). Three studies reported no 
significant differences between African American and Caucasian TNBC women for age 
at diagnosis, p > 0.05 (Chu et al., 2012; Sturtz et al., 2014; Dawood et al., 2009). 
Non-significant, p > 0.05 associations between age at diagnosis and TNBC was found in 
four studies (Stead et al., 2009; Ambrosone et al., 2014; Zaky et al., 2011; Dolle et al., 
2009). Dolle et al. sample had included women less than 45 years of age only. Few 
studies report higher risk for younger aged TNBC women compared to HR+HER2- 
cancer, but these were non-significant findings (Lund et al., 2008; Lund et al., 2010; Telli 
et al., 2011). 
Socio Economic Status (SES) 
Studies with reported findings related to TNBC associations with the variables 
income level, poverty level, insurance status, and education are discussed in this section. 
Significant associations between SES and TNBC were reported by three studies (Llanos 
et al., 2015; Brown et al., 2008; Banegas et al., 2014). Data from CCR for years 
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2000-2013 showed proportions of TNBC women to be high in lowest SES quintile versus 
Luminal A subtype (14.7% versus 10.3% respectively) and low in highest SES quintile 
(23.3% versus 29.8% in Luminal type A) (Parise & Caggiano, 2017). State median 
income of less than $70,000 and education level below college indicated lower SES in a 
study, and TNBC was found to have significant (p < 0.05) higher odds for these two 
categories when compared to Luminal A subtype (Llanos et al., 2015). 
A high frequency of TNBC women were found in low SES compared to high SES in 
a study conducted using California Cancer Registry (Sineshaw et al., 2014, Parise and 
Caggiano, 2014). Four studies reported ethnic differences for SES among TNBC cases 
(Parise & Caggiano, 2017; Sineshaw et al., 2014; Parise & Caggiano, 2017; Banegas et 
al., 2014; Chu et al., 2012). White and Hispanic women from low SES showed an 
increased risk for TNBC, for Black women non-significant association (p > 0.1.99) was 
observed, whereas for API women SES did not make any difference (Parise & Caggiano, 
2017). Among low SES (a composite variable using insurance status and area-level 
median income quartile, used by Sineshaw et al., 2014), compared to NH White, NH 
Black and Hispanic are more likely (79% and 19%, respectively) and API are 20% less 
likely to be TNBC (Sineshaw et al., 2014). However, NH Black had similar higher odds 
even in the high-status strata compared to NH White (Sineshaw et al., 2014). Among 
Hispanic women, Banegas et al. (2014) reported significant associations between lower 
SES and TNBC cases and 1.32-1.42-fold increased risk for TNBC compared to 
HR+HER2- subtype (p < 0.005). Among TNBC cases, Chu et al. (2012) documented 
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significant differences between African American and Caucasian women for mean annual 
income and Caucasian women earned more than African American women (p < 0.001).  
Statistically non-significant (p > 0.05) odds for SES and TNBC were reported by six 
studies (Howlader et al., 2014; Trivers et al., 2009; Zaky et al., 2011; Lund et al., 2010; 
Telli et al., 2011). Different poverty indexes were used by these studies such as county 
level poverty index, federally defined poverty level. Among all breast cancer cases, 
TNBC women fall mostly into low SES compared to high and medium SES levels using 
county level poverty index (14.8% versus 11.4% versus 12.6%, respectively) (Howlader 
et al., 2014). Trivers et al. (2009) reported significant associations (p < 0.05), but 
non-significant higher odds between TNBC and high (>700%) and low SES (<= 200%) 
compared to middle poverty index (201%-700%). Zaky et al. (2011) reported 
non-significant associations between TNBC tumors and SES (< or > than 20% of 
federally defined poverty level). Akinyemiju, Pisu, Waterbor, & Altekruse (2015) 
reported no association between SES and TNBC; the study employed the National 
Cancer Institute’s SES index.  
Significant associations were observed between TNBC and the educational level of 
women. Llanos et al. (2015) compared TNBC to other BC subtypes and showed 57.1% of 
women had less than college level education compared to 48.6% among Luminal A type 
(p = 0.04). Ambrosone et al., reported for an AA sample only study, almost half (49%) of 
the TNBC women had less than high school level education compared to 37% in controls. 
Non-significant associations between education and TNBC reported by two studies 
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(Dolle et al., 2009; Trivers et al., 2009) and no ethnic differences (Sturtz et al., 2014) 
were reported for educational status.  
Sineshaw et al. (2014) reported a significant (p < 0.0001) higher proportion of TNBC 
cases among uninsured (15.8%) and Medicaid-insured (16.4%) compared to other 
insurance types. Non-significant associations between TNBC and insurance status has 
been reported (Llanos et al., 2015; Telli et al., 2011; Trivers et al., 2009; Banegas et al., 
2014). Two studies, Llanos et al., 2015 and Dolle et al., 2009 reported non-significance 
between TNBC and income level (p = 0.3840; p = 0.55 respectively).  
Hormonal Factors Related to TNBC 
 Refer to Table 2.5 for literature citing hormonal risk factors for TNBC. 
Age at Menarche. Seven studies reported their findings on the association between 
age at menarche and TNBC. Significant findings by one study (Shinde et al., 2010) 
identified a borderline significance in one study (Dolle et al., 2009). Five other studies 
identified no associations between these same variables (Llanos et al., 2015; Ma et al., 
2017; Trivers et al., 2009; Ambrosone et al., 2014; Phipps et al., 2011). Women with 
TNBC significantly differed from non-TNBC by younger age at menarche, with a mean 
age of (12.58+1.51y versus 12.75+1.53y (p = 0.03) (Shinde et al., 2010). Non-significant 
ethnic differences were observed between African American and Caucasian women 
(Sturtz et al., 2014).  
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Table 2.5 
Literature Citing Hormonal Risk Factors for TNBC 
Hormonal  
Risk Factors 
Significant findings  
(p < 0.05) 
Non-significant findings 
(p > 0.05) 
Age at 
Menarche 
Shinde et al., 2010 Ma et al., 2017 
Llanos et al., 2015 
Ambrosone et al., 2014 
Phipps et al., 2011 
Trivers et al., 2009 
Borderline significance 
Dolle et al., 2009 
Age at 
Menopause 
Lin et al., 2012 Llanos et al., 2015 
Sturtz et al., 2014 
Phipps et al., 2011 
Hines et al., 2011 
Shinde et al., 2010 
Borderline significance 
Ambrosone et al., 2014 
Age at first 
live birth 
Ambrosone et al., 2014 
Shinde et al., 2010 
Ma et al., 2017 
Phipps et al., 2011 
Trivers et al., 2009 
Dolle et al., 2009 
Use of Oral 
Contraceptive 
Pill 
Bethea et al., 2015 
Beaber et al., 2014 
Dolle et al., 2009 
Llanos et al., 2015 
Ambrosone et al., 2014 
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Parity 
Table 2.5 continued 
 
Palmer et al., 2014 
Phipps et al., 2011 
Shinde et al., 2010 
 
 
 
Ma et al., 2017 
Llanos et al., 2015 
Trivers et al., 2009 
Dolle et al., 2009 
Borderline significance 
Ambrosone et al., 2014 
History of 
Pregnancy 
Losses 
 Phipps et al., 2011 
Dolle et al., 2009 
Breastfeeding Ma et al., 2017 
Shinde et al., 2010 
Kwan et al., 2009 
Llanos et al., 2015 
Trivers et al., 2009 
Dolle et al., 2009 
Note. Articles categorized by variables for hormonal risk factors associated with TNBC. 
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Age at menopause. Significant risk for premenopausal women to develop TNBC 
was reported by one study (Lin et al., 2012). Pre-menopausal women with high body 
mass index was at a significantly higher risk for TNBC compared to post-menopausal 
women (p value for interaction=0.02) (Lin et al., 2012). Another study reported 
borderline significance associations between TNBC versus controls for Menopause, p = 
0.05 (Ambrosone et al., 2014). Five studies reported no association (Llanos et al., 2015; 
Phipps et al., 2011; Shinde et al., 2010; Hines et al., 2011; Sturtz et al., 2014). TNBC 
frequency found to be higher in pre-menopausal status (<=50 years) versus 
post-menopausal status (>50 years), although not statistically significant (Shinde et al., 
2010; Hines et al., 2011). No significant ethnic differences between African American 
and others were documented for menopausal status in TNBC (Sturtz et al., 2014; Dawood 
et al., 2009). 
Age at first live birth. Two studies reported significant associations between age at 
first live birth and TNBC risk (Ambrosone et al., 2014; Shinde et al., 2010). TNBC 
women were reported to be significantly younger than non-TNBC women to have their 
first live birth (mean age for TNBC was 22.48 years compared to 23.97 years for 
non-TNBC women, p < 0.001) (Shinde et al., 2010). Ambrosone et al. also found 
significant associations (p = 0.04) when TNBC cases compared with controls. Four 
studies reported non-significant (p > 0.05) associations between TNBC and age at first 
live birth (Ma et al., 2017; Trivers et al., 2009; Phipps et al., 2011; Dolle et al., 2009). 
Trivers et al. found non-significant increased risk for women who had their first birth less 
than 18 years of age when compared to HR+/HER2-. There were non-significant ethnic 
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differences reported between African American and Caucasian TNBC women for these 
variables (Sturtz et al., 2014).  
Use of Oral Contraceptive Pill (OCP). Studies reported association between OCP 
use and TNBC (Bethea et al., 2015; Dolle et al., 2009; Beaber et al., 2014). Compared to 
controls, TNBC cases had higher odds associated with the self-reported use of OCP, 
especially use within the previous 5 years and the risk significantly (p trend = 0.05) 
declined as years increased (OR = 1.78) (Bethea et al., 2015). The longer the duration of 
OCP use (more than or equal to one year) placed 2.5 times more likely at risk for TNBC 
when compared to non-TNBC women and the risk was significantly higher (P 
heterogeneity=0.008) for women less than 45 years of age (Dolle et al., 2009). When 
comparing TNBC women to other sub-types, OCP use for more than five years, among 
women aged 20-39 years, had a non-statistically significant higher risk (3.7 times) for 
TNBC (Beaber et al., 2014). However, Beaber et al. (2014) reported significant 
association between every single year of OCP use and increase in risk for TNBC when 
compared to ‘never use’ of OCP (p = 0.045). Two studies reported no significant 
associations compared to controls (Llanos et al., 2015; Ambrosone et al., 2014). 
Non-significant ethnic differences were observed between African American and 
Caucasian women (Sturtz et al., 2014).  
Parity. Nine studies identified a link between parity and TNBC. Three of these 
studies found significant associations between parity and TNBC (Shinde et al., 2010; 
Phipps et al.2011; Palmer et al., 2014). Parous (two and three live births) women are at 
significantly higher risk of developing TNBC compared to nulliparous women (Shinde et 
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al., 2010; Palmer et al., 2014) and the risk increased by 37% for ever parous women 
compared to non-parous women (Palmer et al., 2014). Ambrosone et al. (2014) found 
borderline significance for higher odds of women with two or more live births to be 
TNBC. Similarly, Phipps et al. found nulliparity women had a significantly decreased 
risk for TNBC (p = 0.02). Four other studies found no association between parity and 
TNBC (Llanos et al., 2015; Ma et al., 2017; Trivers et al., 2009; Dolle et al., 2009). No 
associations reported between TNBC and history of pregnancy losses (Phipps et al., 2011; 
Dolle et al., 2009).  
Breastfeeding. Breastfeeding was found to be associated with TNBC (Shinde et al., 
2010; Ma et al., 2017; Kwan et al., 2009). TNBC women were more likely to have never 
breastfed (Kwan et al., 2009). Ma et al. (2017) reported a decrease in TNBC risk with 
increasing duration of breastfeeding (Ptrend=0.006) and a 31% decreased risk for parous 
women who breastfed for at least one year compared to those who never breastfed. 
Ambrosone et al. (2014) study reported a decreased risk for women who ever breastfed 
compared to never breastfed and Palmer et al., 2014 reported a 19% decreased risk for 
ever versus never lactation. Women who breastfed for >2 months per child had lesser risk 
for developing TNBC compared to those who did not breastfeed and there is an inverse 
relationship between the duration of breastfeeding and the occurrence of TNBC (Shinde 
et al., 2010). Llanos et al. (2015), Trivers et al., Dolle et al. (2009) found no associations 
between breast-feeding and TNBC. Phipps et al. found no associations between the 
length of breastfeeding duration with TNBC risk.  
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Significant ethnic differences were observed between African American and 
Caucasian parous women with TNBC, a Caucasian woman were more likely to breast 
feed (p < 0.001) (Sturtz et al., 2014). However, Ma et al., (2017) reported that age and 
race modified the association between TNBC and breastfeeding. AA women who 
breastfed 6 months or longer and between the ages 20-44 years were reported to have 82% 
lesser risk for TNBC compared to their counterparts who never breastfed. 
Obesity. Obesity was reported in the literature to have a significant (p < 0.05) 
association with TNBC compared to ER/PR+HER2- and controls (Trivers et al., 2009). 
Postmenopausal high and recent BMI was associated with decreased risk (Bandera et al., 
2015; Chen et al., 2016) but high BMI in premenopausal was reported to have different 
findings. Bandera et al. reported no association of obesity with TNBC, but Chen et al. 
(2016) and Kwan et al. (2009) found higher odds for TNBC among premenopausal obese 
women. Premenopausal obese women had 82% increased risk for TNBC (Luminal A 
referent) compared to women whose BMI was less than 25 Kg/m2 (Chen et al., 2016). 
Inconsistent findings could be due to sample numbers, Chen et al. (2016) study sampled 
2659 women aged 20-69 years from different ethnicities, whereas Bandera et al. studied 
women from the AMBER consortium, only African American women (2,104 cases and 
12,060 controls). Lin et al. found borderline significance (p = 0.052) for BMI differences 
among TNBC cases. In their study women with BMI >30 kg/m2 was associated with 
TNBC risk compared to BMI 25-30kg/m2 and <25 kg/m2 (Lin et al., 2012). No 
associations between BMI and TNBC were reported by four studies (Llanos et al., 2015; 
Stead et al., 2009; Dolle et al., 2009; Ambrosone et al., 2014). When assessed for ethnic 
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differences among TNBC cases, AA women compared to White women were 
significantly (p = 0.024) more likely to be obese (Sturtz et al., 2014). Elevated Waist Hip 
Ratio had stronger association with TNBC (Bandera et al., 2015).  
Hormone Replacement Therapy (HRT). Shinde et al. (2010) observed differences 
between TNBC and non-TNBC cases for use of HRT and the duration of HRT use was 
significantly less among TNBC cases (3.38 years versus 4.53 years, p = 0.002). Chen et 
al. (2016) reported that TNBC women were more likely to be users of estrogen-only HRT 
next only to Luminal A subtype (6.8% versus 4.6% respectively), however not a 
statistically significant finding. Two studies found no associations between HRT and 
TNBC (Llanos et al., 2015; Ambrosone et al., 2014). Among postmenopausal women, 
non-significant ethnic differences observed between African American and Caucasian 
TNBC women who used HRT (Sturtz et al., 2014).  
Other Risk Factors 
Other TNBC risk factors were studied with varying results. Smoking status identified 
no significant (p > 0.05) associations reported by five studies, (Park et al., 2016; Rana, 
2009; Dolle et al., 2009; Ambrosone et al., 2014; Trivers et al., 2009). The risk for TNBC 
was significantly (p = 0.03) twice among African-American women compared to White 
women for alcohol consumption of >7 drinks per week (Williams, Olshan, Tse, Bell, & 
Troester, 2016) with Trivers et al. and Dolle et al. reported no association with alcohol 
consumption. Trivers et al. reported no association with physical activity in the year 
before cancer diagnosis (p > 0.05), Caffeine intake was identified as having ethnic 
differences among TNBC cases (Sturtz et al., 2014). Among TNBC cases, safe/moderate 
65 
 
intake (<500mg/day) of caffeine intake was high among African American women 
compared to high/extremely high intake among Caucasian women (p < 0.001) (Sturtz et 
al., 2014). Similarly, among TNBC cases alcohol consumption was significantly (p < 
0.05) less for African American women compared to Caucasian women), but smoking 
and physical activity did not differ significantly (p = 0.757, 0.138 respectively) between 
African American and Caucasian women (Sturtz et al., 2014).  
Non-significant associations between marital status and TNBC was reported by a 
study (Llanos et al.). Another study reported non-significant (p = 0.671) ethnic 
differences observed between African American and Caucasian TNBC women for 
marital status (Sturtz et al., 2014). Llanos et al. (2015) reported women with TNBC 
tumors to be less likely (OR = 0.6) to have history of benign breast disease compared to 
Luminal A subtype, but no association was reported by Ambrosone et al.  
Maiti et al. (2009) identified an association between TNBC and Metabolic syndrome. 
When compared to Non-TNBC a higher percentage of TNBC women had a Metabolic 
syndrome diagnosis (36.7% versus 58.1% respectively, p = 0.004) based on the National 
Cholesterol Education Program (Maiti et al., 2009). Similar results were observed from 
information based on a study by the American Association of Clinical Endocrinologists 
(52.3% in TNBC versus 34.3% in Non-TNBC, p = 0.017) (Maiti et al., 2009).  
Ethnic Differences in Prevention, Early Detection, and Treatment 
Prevention of TNBC  
In regards to prevention of TNBC, few studies discussed genetic testing and 
counseling (Ricks‐Santi & McDonald, 2016; Thompson et al., 2012; Lynce et al., 2015; 
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Armstrong et al., 2015; Cragun et al., 2015; Sussner et al., 2009). Healthcare provider 
referral and race/ethnicity were documented to be significant factors in having germline 
genetic testing (Cragun et al., 2015; Thompson et al., 2012).  
Factors associated with receiving genetic counseling and healthcare provider referral 
for genetic testing were investigated in two studies. The variables of healthcare provider 
referral, household income >$35,000 in the year prior to diagnosis, and insured with a 
private health insurance were strongly associated with receiving genetic counseling 
(Cragun et al., 2015). The study by Cragun et al. was conducted among 440 Black 
women with age at diagnosis <50 years. The variables that were associated with a 
healthcare provider referral were college education (Cragun et al., 2015; Armstrong et al., 
2015), age at diagnosis less than 45 years of age (Thompson et al., 2012; Cragun et al., 
2015), NH White (Armstrong et al., 2015), married (Armstrong et al., 2015), higher 
incomes (Armstrong et al., 2015) and TNBC status (Cragun et al., 2015). Younger age at 
diagnosis (<50 years) had significantly five times higher odds (p < 0.001) of getting 
tested for BRCA compared to women aged >50 years (Vig et al., 2013). Cragun et al. 
indicated that socioeconomic factors and healthcare provider referrals may possibly 
contribute to the genetic services access disparities among underserved minority 
population. 
The American BRCA Outcomes and Utilization of Testing (ABOUT) study found 
that lower rates of genetic counseling prior to testing was lowest among patients of 
obstetricians/gynaecologists (Armstrong et al., 2015). Similarly, the women in an 
oncology setting were significantly likely to receive physician recommendation for 
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germline genetic testing and counseling compared to other recruitment methods such as 
research contact database, genetic counselor, and community groups (p = 0.03,0.03, 
0.0001, respectively) (Thompson et al., 2012). Sussner’s research group (2009) assessed 
for predictors of intention for genetic counseling and showed that at-risk Latinas with 
“competing life concerns” were significantly less likely to undergo BRCA genetic 
counseling, p = 0.0002 (Sussner et al., 2009). Other documented significant predictors of 
the intention to genetic counseling were the perceived risk of carrying a BRCA mutation 
and referral by their physician (Sussner et al., 2009). Other non-significant predictors for 
the intention to make an appointment in the next 6 months were positive attitudes about 
genetic counseling, age, personal diagnosis of breast cancer, and family history of breast 
cancer in a first degree relative (Sussner et al., 2009). 
 Physician recommendation for genetic testing and counseling was reported to be 
significantly lower among less educated Black women (high-school degree or less), 
Black women with no insurance and foreign-born Black women (Thompson et al., 2012). 
This study, conducted among African American only (n=125 and 40% born outside The 
United States), found statistically significant (p = 0.03) independent associations between 
younger women (<45 years of age) and physician recommendation for genetic counseling 
(Thompson et al., 2012). Thompson et al. (2012) recommended development of specific 
interventions for Black women for all ages to reduce racial disparity. Han et al. (2015) 
suggested the development of a risk assessment model based on the Genetic Risk 
Assessment Score and other risk factors to identify women high risk for breast cancer.  
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MacNew, Rudolph, Brower, Beck, & Meister (2010) recommended educational 
efforts on BRCA testing and its benefits to be focussed on less educated and minority 
groups. Statistical associations were found between knowledge about breast cancer genes 
and ethnicity, but not with age and religion by MacNew et al. (2010). Among Caucasians, 
African Americans, and Hispanic/others it was found that a higher proportion of 
Caucasians than the other ethnic groups had the knowledge of breast cancer genes (67.3%, 
p = 0.000) (MacNew et al., 2010). Similarly, women with graduate school education and 
an income greater than $100 000 were statistically significant (p = 0.003, 0.022 
respectively) in higher proportions to have knowledge about genetic testing and genes 
compared to other levels of education (MacNew et al., 2010). Women with a positive 
family history of breast cancer were at significantly higher odds of having knowledge 
about the role of mutated genes in developing breast cancer and significantly (p = 0.001) 
more likely to know about genetic testing, whereas having a personal history of breast 
cancer did not have an impact on knowing genes, testing and choosing a genetic test (p > 
0.05) (MacNew et al., 2010).   
Early detection of TNBC 
Findings from studies suggest that early identification of TNBC risk factors among 
women and recommendation of genetic testing/counseling as well as regular screening 
may help with early detection of TNBC (Sharma et al., 2014; Lin et al., 2012; Llanos et 
al., 2015). Findings from the study by Sharma et al. (2014) also concluded that age at 
TNBC diagnosis and significant family history were significant (p < 0.0001 for both) 
predictors of BRCA mutation status. Llanos et al. (2015), reported that there are higher 
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odds for TNBC tumors to be self-detected compared to Luminal A subtype (OR 2.7, 
95%CI 1.7-4.2). Only 36.5% of Luminal A tumors were self-detected compared to 60.5% 
of TNBC tumors (Llanos et al.). Lin et al. found that one-third of the TNBC patients 
self-detect their tumors and a significantly smaller number of women clinically present 
based on abnormal screening mammogram (29% vs 48%, p < 0.0001). Women with 
TNBC present more often with symptoms when compared to those with HR+HER2- 
cancers (68% vs 48%, p < 0.001) (Lin et al., 2012).  
One study’s finding highlights the need for evaluation of risk factors in women 
(</>60 years) and helps to identify TNBC women who may benefit from BRCA genetic 
testing (Rummel et al., 2013). On comparing BRCA1 mutation frequency based on age 
(less/more than 60 years) and significant risk factors, it was found that patients with 
BRCA1 mutation along with risk factors had higher TNBC frequency compared to those 
without significant risk factors (11.2-18.3% versus 4.6% for age <60 years and 3.5%-7.7% 
versus 2.3% for age >60 years) (Rummel et al., 2013). Risk factors were based on the 
Hereditary Breast and Ovarian Cancer Syndrome Testing criteria by the National 
Comprehensive Cancer Network (Rummel et al., 2013).  
TNBC Treatment 
Plasilova et al. (2016) reported significant differences among types of breast cancer 
for chemotherapy and surgery. There were 81.4% of TNBC cases that underwent 
chemotherapy compared to 34.9% in HR+/HER2-, 75.2% in HR+/HER2+, and 84.5% 
among HR-/HER2+. Among Breast Conservation Therapy patients, TNBC there were 
significant differences from non-TNBC cases for use of chemotherapy (p = 0.007) and 
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hormone therapy (p < 0.0001) and no differences for completion of radiotherapy (Zaky et 
al., 2011). TNBC women were significantly more likely to receive chemotherapy (69.7% 
versus 40% in non-TNBC cases, p = 0.007), and less likely for hormone therapy (3% 
versus 79.4% among non-TNBC cases) (Zaky et al., 2011). There were no differences 
noted for completion of radiotherapy between TNBC and non-TNBC tumors (Zaky et al., 
2011). Recurrence Free Survival at five years was significantly higher for TNBC women 
with a BRCA mutation versus wild-type status, 86.2% versus 51.7%, p = 0.031 
(Gonzalez-Angulo et al., 2011). No significant differences were identified between 
African American and Caucasian TNBC women for systemic treatment obtained, but 
significant differences (p = 0.01) for type of surgery (Mastectomy versus Breast 
Conserving therapy) (Chu et al., 2012). There were 81% versus 63% who opted for 
mastectomy among Caucasian and African American TNBC women, respectively (Chu et 
al., 2012). Plasilova et al. (2016) reported that TNBC had significantly lesser odds for 
surgery (p = 0.009) and chemotherapy (p < 0.001) treatments compared to HR+/HER2-. 
Two studies compared African American and White/other women for patient 
outcomes after primary systemic chemotherapy; only one found significant (p = 0.001) 
ethnic differences (Balmanoukian et al., 2009). The study aimed at finding if racial 
differences existed in pathologic Complete Response/pCR to treatment (Balmanoukian et 
al., 2009). Among TNBC cases post Primary Systemic Therapy (PST) they found that 
compared to White/other women (n=23), African American women (n=15) were more 
likely to suffer recurrence and death and had less chances of achieving pCR, (13% versus 
52% among White/other, p = 0.001) (Balmanoukian et al., 2009). Significant differences 
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between African American and White/other women after PST exist for recurrence free 
survival (p = .045) and overall survival (p = .028) and that both are shorter in duration for 
African American women (Balmanoukian et al., 2009). However, Dawood et al. found no 
significant differences (p = .302) between Black and White/others patients (only TNBC 
cases who underwent primary systemic chemotherapy, n=471) in overall survival (OS) 
and recurrence-free survival (RFS) and that race was not associated with survival 
outcomes. They stated that pCR was not affected by race (Dawood et al., 2009). Dawood 
et al. found no significant (p = .341) differences between African Americans and others 
for the type of chemotherapy used (Taxane only, anthracycline only, 
Taxane/anthracycline combination, and other), type of surgery (mastectomy versus 
segmental), and radiotherapy usage (yes/no). More research is needed to assess the true 
associations between race and survival outcomes after treatment (Balmanoukian et al., 
2009). 
Summary 
In summary, the literature review on TNBC provided the available incidence, 
frequency of TNBC. The original search retrieved 900 articles and 85 articles were 
selected for the review based on the selection criteria. It described the TNBC phenotypic 
and genotypic traits and examined ethnic differences among TNBC phenotype and 
genotype. Risk factors related to TNBC, ethnic differences for risk factors were stated. 
Finally, ethnic differences for prevention, early detection, and treatment of TNBC were 
discussed.  
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Many knowledge gaps were identified when the last ten years’ literature were 
reviewed. TNBC ranked next to HR+/HER2- in frequency and the most recent TNBC 
incidence rate was published in 2014 and 2015. Mixed results (statistically significant and 
non-significant) were observed from literature on phenotypic, demographic, and 
treatment characteristics of TNBC tumors. Studies reported mutations mainly in BRCA 1/ 
2 and few other genes, Single Nucleotide Polymorphisms, and Variants of Uncertain 
Significance. Risk factors that majorly contributed to TNBC were country of origin, 
race/ethnicity, age at diagnosis, socio economic status, family history, BRCA mutations, 
reproductive factors, obesity, hormone replacement therapy, and others. Research 
questions were developed based on the identified gaps in the literature. 
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CHAPTER 3 
TNBC INCIDENCE RATES; PHENOTYPIC, DEMOGRAPHIC AND 
TREATMENT CHARACTERISTICS OF TNBC  
AMONG WOMEN OF COLOR 
Submitted on 7/30/2017, Oncology Nursing Forum 
Introduction 
 Triple Negative Breast Cancer (TNBC) is a breast tumor that lacks Estrogen 
Receptor, Progesterone Receptor, and is Human Epidermal Growth Receptor 2/neu 
negative (Goldhirsch et al., 2011). It has the worst breast specific and overall survival rate 
(Lin et al., 2012), a higher proportion of local and distant metastasis rates (Zaky et al., 
2011), and is treated by Breast-conserving surgery (lumpectomy), neoadjuvant treatment, 
and adjuvant systemic therapy (TNBC Treatment, 2017). Studies on TNBC have been 
done predominantly on the Non-Hispanic White and Non-Hispanic Black population, 
whereas Hispanic and Asian sub-groups have been understudied (Howlader et al., 2014; 
Kohler et al., 2015; Llanos et al., 2015). TNBC statistics on Asian sub-groups can be 
misleading as they are grouped under one race such as “Asian/Pacific Islander.” Although 
literature has evidence of information on TNBC clinical behaviour on major racial groups 
like Non-Hispanic White and Non-Hispanic Black (Chu, Henderson, Ampil, & Li, 2012; 
Dawood et al., 2009; Pacheco, Gao, Bumb, Ellis, & Ma, 2013; Sturtz, Melley, Mamula, 
Shriver, & Ellsworth, 2014; Sullivan et al., 2014), there is a lack of any large-scale study 
that includes Asian sub-groups. 
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Purpose of the Study 
The problem statement and gaps in literature lead to the following research questions 
and hypotheses. 
Question and Research Hypothesis 
a) Is there a difference in age-adjusted and age-specific incidence rates for TNBC 
among races/ethnicities? 
There will be significantly higher age-adjusted rate for Non-Hispanic Black 
compared to Non-Hispanic White, Hispanics, and Asian / Pacific Islander; for 
age-specific incidence rate, Non-Hispanic Black women will have the highest rate and 
Hispanics, Asian and Pacific Islander women will have the lower rates when compared to 
Non-Hispanic White women. 
Question and Research Hypothesis  
b) Are there differences in phenotypic, demographic, and treatment features of 
TNBC tumors among races/ethnicities? 
There will be significant differences between races/ethnicities for phenotypic, 
demographic, and treatment characteristics of TNBC tumors. 
Aim of Study 
The aim of this study was to determine the TNBC age-adjusted and age-specific 
incidence rates among races/ethnicities using Surveillance, Epidemiology, and End 
Results (SEER) Program data from the National Cancer Institute. Differences in clinical 
and pathologic features of TNBC tumors among races/ethnicities were also assessed. The 
SEER Program covers over 28% of the United States (U. S.) population on cancer 
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incidence and survival. It collects information from population-based cancer registries 
across the U.S. and covers 26% of African American, 38% of Hispanics, and 50% of 
Asians (Population Characteristics, n. d.). In this study, 22,908 TNBC cases diagnosed 
from 2010 to 2013 were analysed for TNBC incidence rates, and clinico-pathologic 
characteristics of TNBC among Non-Hispanic White, Non-Hispanic Black, Hispanic (All 
Races), Chinese, Asian Indian, Korean, Vietnamese, and Filipina women.  
Methods 
 This is a cross-sectional retrospective population-based study with secondary data. 
Data was included from all 18 SEER cancer registries for identified women diagnosed 
with primary invasive breast cancer during the years 2010-2013. The 18 cancer registries 
included the Alaska Native Tumor Registry, Atlanta, Connecticut, Detroit, Greater 
California, Greater Georgia, Iowa, Kentucky, Louisiana, Los Angeles, New Mexico, New 
Jersey, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, and Utah.  
The SEER population is comparable to the general U. S. population in regards to 
poverty and education. The proportion of foreign-born persons is higher among SEER 
compared to general U. S. population (Population Characteristics, n. d.). One of the sites 
directly linked to SEER cases was the American Community Survey 2010-2014. 
SEER*Stat software was used to provide caselisting of the county attributes. 
All study related data was obtained from SEER database after signing a Research 
Data Agreement for internet data access. SEER*Stat software Version 8.3.2 was used for 
data collection and analysis (SEER Statistical Software, n. d.). The SEER Research 
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incidence data used for the study was from the November 2015 submission. Exempt 
review approval from Clemson University Institutional Review Board was also obtained.   
TNBC women with their race/ethnicity recorded as Non-Hispanic White, 
Non-Hispanic Black, Hispanic, Chinese, Asian Indian, Korean, Vietnamese, and Filipina, 
and age 18 years and older were selected for the study. Chinese, Asian Indian, Korean, 
Vietnamese, and Filipina are the fastest growing Asian population in the U.S. and hence 
were included in the study (Hoeffel, Rastogi, Kim, & Shahid (2012). The Hispanic 
women in this study included Hispanics from all races. For the dependent variable, the 
Breast Subtype, “Triple Negative” category was selected. SEER*Stat was used to create a 
case listing for primary TNBC female malignant cases aged 18 years and above from the 
eight race/ethnic groups in all 18 registries. Other variable information extracted for these 
women were age at diagnosis, American Joint Committee on Cancer/AJCC stage, size of 
tumor, tumor histology, tumor grade, lymphnode invasion, metastasis, and treatment 
(chemotherapy, radiation, surgery).  
Data extracted from the SEER database was saved as a raw file in SPSS. Since SEER 
gives a unique ID to each case, there were no duplicates. The total number of TNBC case 
information extracted for the raw file was 22,909. One case was excluded due to an age 
less than 18 years; a total of 22,908 cases were included in the analysis. The median age 
at diagnosis was calculated for all TNBC cases. Women who were classified as 85+ years 
were coded as 85 and median age was calculated for all TNBC women aged 18 years and 
above. Women were grouped into two age categories; less than 40 years and greater than 
40 years. Since women less than 40 years of age are not routinely screened for breast 
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cancer a cut-off at 40 years was used to categorize. Also, the literature indicates that 
women less than 40 years of age will more frequently develop TNBC (Parise & Caggiano, 
2017; Sineshaw et al., 2014) . 
AJCC Stage was used as coded to assist with data analysis; stages IA and IB were 
coded as I, stages IIA, and, IIB as stage II, stages IIIA, IIIB, IIIC, and IIINOS as stage III, 
and Stage IV stood alone. There were 52 cases diagnosed at Stage 0 and excluded from 
analysis because this stage is a non-invasive cancer and the study’s scope was only 
invasive cancers. Tumor Histology was based on the SEER codes including 8500/3: 
Infiltrating duct carcinoma, NOS (Non-Specific), 8520/3: Lobular carcinoma, 
NOS(Non-Specific), and 8522/3: Infiltrating duct and lobular carcinoma. Tumor 
histology outside of these categories were classified as “others.” There were 3,156 TNBC 
cases with histology in the “other” classification.  
The classification of Tumor Grade included: “Well differentiated; Grade I” coded as 
Grade I, “Moderately differentiated; Grade II” as Grade II, “Poorly differentiated; Grade 
III” as Grade III and “Undifferentiated; anaplastic; Grade IV” as Grade IV. For tumor 
stage and tumor grade, unknown cases were classified as a separate category. 
SEER data has tumor size entered in numeric value (millimeters) and some cases 
have information as “values under review”, “no primary tumor found, no Paget’s disease”, 
“microscopic focus of foci only”, “mammography/xerography diagnosis with no size 
given”, “diffuse”, “unknown”, “3 mm or less than 3mm”, “Paget disease of nipple with 
no demonstrable tumor.” Median tumor size calculation did not include the 
above-mentioned categories because they are not numerical values to include in median 
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calculation and the only category included was “3mm or less than 3mm”. The category “3 
mm or less than 3mm” was coded as 3mm and was included in median tumor size 
calculation.  
Lymph node invasion was categorized as yes or no. All cases that had a N1, N2 or 
N3 were coded as “yes” and those with N0 as “no.” There were 355 cases with NX 
(lymph nodes cannot be evaluated) and 34 cases had NA (Not Applicable); both groups 
were excluded from the analysis. Similarly, 34 cases had an NA for Metastasis and were 
excluded from analysis. M0 and M0 (i+) were grouped as “no” and M1 as “yes.”  
The three variables for treatment are chemotherapy, surgery, and radiation. SEER 
does not have hormone therapy information on all data in the November 2015 submission. 
Currently SEER is collecting hormone therapy information as part of treatment data for 
cancer cases. An additional agreement was signed by the Principal Investigator before 
online access was obtained for chemotherapy information on all study cases as the earlier 
data did not have chemotherapy information. The database used was Incidence-SEER 18 
Regs Custom Data (with chemotherapy recode), Nov 2015 Sub (2000-2013) identical to 
Incidence- SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, 
Nov 2015 Sub (2000-2013). A “yes” for chemotherapy indicates that the patient had 
chemotherapy as part of first line of treatment and a “no” indicates chemotherapy was not 
given or it is unknown (SEER*Stat Technical support, personal communication, August 5, 
2016). Note, this can introduce bias when interpreting results and can be a potential threat 
to external validity of the study. Noone et al. (2016) reported an overall 68% of 
sensitivity for SEER chemotherapy information, but high specificity; if chemotherapy 
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information is provided by SEER it was most likely received by the patient (Noone et 
al.).  
Radiation information in SEER was coded as follows: “beam radiation, combination 
of beam with implants or isotopes, radiation, NOS method of source not specified, 
radioactive implants, radioisotopes” coded as yes, “none” as no, “recommended, 
unknown if administered”, “unknown”, and “refused” as it is.  
Surgery was coded as: “surgery performed” as yes, “not recommended, 
recommended but not performed, patient refused; recommended but not performed, 
unknown reason; not recommended, contraindicated due to other cond; autopsy only 
(1973-2002); not performed, patient died prior to recommended surgery” as no, and 
“unknown; death certificate; or autopsy only (2003+); recommended, unknown if 
performed” as unknown. 
Statistical Analyses 
The age-adjusted incidence rate was calculated using SEER*Stat software. Age 
groups ranging from 20 years and above were selected for incidence rate calculation. 
None of the TNBC cases were between 18 and 20 years of age. Rates were obtained for 
individual races/ethnicities; Non-Hispanic/NH White, NH Black, Hispanic but not for the 
ethnicities of Chinese, Asian Indian, Vietnamese, Korean, and Filipino. This is because 
SEER has TNBC case counts but not the population counts for those individual 
ethnicities. Hence rates were calculated for Asian and Pacific Islander as one group. 
However, when comparing clinico-pathologic characteristics among ethnicities, available 
individual ethnicity information was used. All rates were age-adjusted to the U. S. 
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Standard Population (19 age-groups-Census P25-1130). The age-groups range in five 
years: 20-24 years, 25-29 years, 30-34 years, 35-39 years, 40-44 years, 45-49 years, 
50-54 years, 55-59 years, 60-64 years, 65-69 years, 70-74 years, 75-79 years, 80-84 years, 
and 85+ years.  
Statistical software SPSS version 24 was used for comparing TNBC 
clinico-pathologic characteristics among the eight groups. Chi-square tests were 
employed to compare frequency distributions among the eight ethnic groups for TNBC 
clinico-pathologic characteristics including age at diagnosis (less than or greater than 40 
years), tumor histology, tumor grade, tumor stage, lymph node invasion, metastasis, and 
treatment (chemotherapy, radiation, surgery). Microsoft excel was used to convert the 
string values to numerical values (20mm converted 20) and then SPSS was used to 
calculate median age at diagnosis and median tumor sizes. A p value of less than or equal 
to 0.05 was considered to have statistical significance. 
Results 
The 18 SEER registries included 22,908 women with a primary breast cancer 
diagnosis of TNBC, age > 18 years for the years 2010-2013. TNBC Incidence rates per 
100,000 were standardized to the year 2000 United States Standard population (19 age 
groups-census P25-1130) and calculated for NH White, NH Black, Hispanic, and Asian 
Pacific Islander categories/populations (See Table 3.1). Rates were standardized to the 
US Census 2000 general population as it is the most recent census population available 
with SEER (Standard Populations, n. d.). NH Black had the highest incidence rate, 
516.17 (all rates per 100,000), followed by NH White 287.92 and Hispanics 212.91. The 
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lowest incidence rate among the four-major race/ethnicities was 190.60 for the Asian 
Pacific Islander category. (See the Methods section for explanation of the collective 
incidence rate for the Asian Pacific Islander population instead of five ethnic groups.) 
TNBC age-specific rates were calculated for 14 age groups that fell within the 
study’s age limit. There were no TNBC cases under age 20 years and the 14 remaining 
age groups are 20-24 years, 25-29 years, 30-34 years, 35-39 years, 40-44 years, 45-49 
years, 50-54 years, 55-59 years, 60-64 years, 65-69 years, 70-74 years, 75-79 years, 
80-84 years, and 85+ years. See Table 3.1 and Figure 3.1 for age-specific rates per 
age-group for the major races, rates per 100,000 women standardized to the U. S. 
population. Among NH White women ages 70-74 years had the highest age-specific rate 
followed by those 65-69 years (35.84 and 33.65 per 100,000 respectively). Among NH 
Black women, the 60-64 age group had the highest rate followed by those 65-69 years 
(62.43 and 59.41 per 100,000 respectively). For Hispanic women, 65-69 years has the 
highest rate followed by those 70-74 years of age (24.81 and 22.54 per 100,000 
respectively). Asian / Pacific Islander women was the only group with the highest 
age-specific rate for women aged 80-84 years followed by those 65-69 years (20.73 per 
100,000).  
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Table 3.1 
TNBC Age-Specific and Age-adjusted incidence rates for the year 2010-2013 
AGE-ADJUSTED AND AGE-SPECIFIC INCIDENCE RATES 
Years NH White NH Black Hispanic 
(All Races) 
NH Asian 
 Pacific 
 Islander 
Standard 
Populationa 
20-24 0.17 0.348 0.18 0.164 18,257,225 
25-29 1.706 3.383 1.627 1.450 17,722,067 
30-34 5.431 8.452 4.299 3.575 19,511,370 
35-39 9.5 16.761 9.263 7.182 22,179,956 
40-44 15.99 25.762 12.639 10.472 22,479,229 
45-49 19.532 37.225 17.338 14.173 19,805,793 
50-54 22.793 48.84 19.222 16.287 17,224,359 
55-59 25.434 53.451 19.881 16.910 13,307,234 
60-64 30.446 62.429 22.539 18.794 10,654,272 
65-69 33.648 59.413 24.808 20.971 9,409,940 
70-74 35.843 58.247 22.273 20.803 8,725,574 
75-79 32.032 59.845 19.538 20.677 7,414,559 
80-84 31.209 44.977 21.47 22.084 4,900,234 
85+ 24.188 37.034 17.837 20.072 4,259,173 
Total 287.922 516.167 212.914 193.614  
Unknown ~ ~ ~ ~  
Note. Rates are per 100,000 and age-adjusted to the 2000 US Standard Population (19 
age groups - Census P25-1130) standard 
Text in bold are the peak age-groups for each race/ethnic group 
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Figure 3.1 
TNBC Age-Specific Incidence Rate (2010-2013) 
Note. Rates are per 100,000 and age-adjusted to the 2000 United States Standard 
Population (19 age groups - Census P25-1130)  
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TNBC Phenotypic and Treatment Differences among races/ethnicities 
Significant differences were observed among eight groups for TNBC median age at 
diagnosis. See Table 3.2. Asian Indian women were the youngest among all eight groups 
of TNBC with a median age of 47 years, followed by Hispanic women 52 years of age 
and Vietnamese women 55 years of age. The other groups ranged between 56-60 years. 
When TNBC women were categorized as less than 40 years and greater than 40 years, 
Asian Indian women were the significantly highest proportion followed by Hispanics and 
Vietnamese in the less than 40 years’ age-group (30.5%, 19.1% and 17.6% respectively, 
p < 0.001). Among TNBC women aged greater than 40 years, NH White women, NH 
Black women, and Filipina women were the leading groups (92.4%, 89.5%, and 89.3% 
respectively). The differences among races/ethnicities based on age-groups was 
statistically significant (p < 0.001). Refer Table 3.3 for demographic characteristics 
among women of color. 
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Table 3.2 
TNBC Phenotypic, Demographic Differences Among Races/Ethnicities. 
*p < 0.001, **p = 0.037 
 
Variable
*
 Non-Hispanic 
White 
Non-Hispanic 
Black 
Hispanic  
(All 
Races) 
Chinese Asian 
Indian 
Filipina Korean Vietnamese 
Median age 
at 
diagnosis, 
years 
60 56 52 56 47 57 56 55 
Age Groups 
<40 years 
1107 
7.6% 
489 
10.5% 
531 
19.1% 
30 
10.9% 
40 
30.5% 
38 
10.7% 
18 
14.3% 
15 
17.6% 
>40 years 13386 
92.4% 
4169 
89.5% 
2254 
80.9% 
246 
89.1% 
91 
69.5% 
316 
89.3% 
108 
85.7% 
70 
82.4% 
<40 years: 
>40 years 
1:12.16 1:8.52 1:4.24 1:8.17 1:2.28 1:8.35 1:5.99 1:4.68 
Stage At 
Diagnosis 
        
I (5513) 
38.1% 
(1290) 
27.7% 
(756) 
27.2% 
(102) 
37.0% 
(42) 
32.3% 
(109) 
31.0% 
(40) 
31.7% 
(26) 
30.6% 
II (5787) 
40.0% 
(2029) 
43.6% 
(1303) 
46.9% 
(126) 
45.7% 
(64) 
49.2% 
(156) 
44.3% 
(56) 
44.4% 
(41) 
48.2% 
III (2031) 
14.0% 
(858) 
18.5% 
(480)  
17.3% 
(26) 
9.4% 
(18) 
13.8% 
(58) 
16.5% 
(17) 
13.5% 
(11) 
12.9% 
IV (854) 
5.9% 
(370) 
8.0% 
(148) 
5.3% 
(16) 
5.8% 
(5) 
3.8% 
(18) 
5.1% 
(6) 
4.8% 
(5) 
5.9% 
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Table 3.2 continued 
Unknown 
Stage 
(287) 
2.0% 
(103) 
2.2% 
(92) 
3.3% 
(6) 
2.2% 
(1) 
0.8% 
(11) 
3.1% 
(7) 
5.6% 
(2) 
2.4% 
Tumor size 
(median, 
cms) 
(N=21527) 
2.2 2.5 2.5 2.2 2.45 2.4 2.3 2.5 
Tumor 
Histology** 
Ductal 
(12057) 
96.7% 
(3950) 
98.0% 
(2329) 
96.9% 
(233) 
97.1% 
(118) 
98.3% 
(286) 
96.3% 
(113) 
97.4% 
(77) 
100.0% 
Lobular (206) 
1.7% 
(40) 
1.0% 
(33) 
1.4% 
(4) 
1.7% 
(0) 
- 
(7) 
2.4% 
(1) 
0.9% 
(0) 
- 
Mixed (204) 
1.6% 
(41) 
1.0% 
(42) 
1.7% 
(3) 
1.3% 
(2) 
1.7% 
(4) 
1.3% 
(2) 
1.7% 
(0) 
- 
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Table 3.3 
Demographic Characteristics Among TNBC Women of Color 
* p < 0.001 
 
Variable
* Non-Hispanic 
White 
Non-Hispanic 
Black 
Hispanic 
(All 
Races) 
Chinese Filipina Vietnamese Korean Asian  
Indian 
Median Household Income (in tens) 
$1915-3999 1140 690 72 1 0 1 0 1 
 7.9% 14.8% 2.6% 0.4% 0.0% 1.2% - 0.8% 
$4000-4999 2881 1291 441 2 15 4 3 10 
 19.9% 27.7% 15.8% 0.7% 4.2% 4.7% 2.4% 7.6% 
$5000-5999 4101 1483 1294 88 120 22 54 25 
 28.3% 31.8% 46.5% 31.9% 33.9% 25.9% 42.9% 19.1% 
$6000-6999 3035 638 430 19 66 7 12 9 
 20.9% 13.7% 15.4% 6.9% 18.6% 8.2% 9.5% 6.9% 
$7000-7999 2054 381 340 116 121 39 41 34 
 14.2% 8.2% 12.2% 42.0% 34.2% 45.9% 32.5% 26.0% 
$8000-8999 714 119 98 7 7 0 12 19 
 4.9% 2.6% 3.5% 2.5% 2.0% - 9.5% 14.5% 
$9000-9999 474 38 103 42 24 12 4 28 
 3.3% 0.8% 3.7% 15.2% 6.8% 14.1% 3.2% 21.4% 
$10000-12397 92 18 6 1 1 0 0 5 
 0.6% 0.4% 0.2% 0.4% 0.3% - - 3.8% 
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Table 3.3 (continued) 
Variable
* Non-Hispanic 
White 
Non-Hispanic 
Black 
Hispanic 
(All Races) 
Chinese Filipina Vietnamese Korean Asian  
Indian 
Insurance 
Uninsured 240 206 150 5 7 2 5 4 
 1.7% 4.4% 5.4% 1.8% 2.0% 2.4% 4.0% 3.1% 
Insured 10781 2695 1479 197 250 38 72 91 
 74.4% 57.9% 53.1% 71.4% 70.6% 44.7% 57.1% 69.5% 
Any Medicaid 1308 1024 802 45 56 28 32 15 
 9.0% 22.0% 28.8% 16.3% 15.8% 32.9% 25.4% 11.5% 
Insured/No specifics 1939 656 312 26 34 15 14 18 
 13.4% 14.1% 11.2% 9.4% 9.6% 17.6% 11.1% 13.7% 
Unknown 225 77 42 3 7 2 3 3 
 1.6% 1.7% 1.5% 1.1% 2.0% 2.4% 2.4% 2.3% 
Persons below poverty Percent 
1.04-9.99% 2287 279 251 66 83 17 32 55 
 
15.8% 6.0% 9.0% 23.9% 23.4% 20.0% 25.4% 42.0% 
10-19.99% 9943 2941 2118 206 257 65 93 67 
 68.6% 63.1% 76.1% 74.6% 72.6% 76.5% 73.8% 51.1% 
20.52-52.63% 2261 1438 415 4 14 3 1 9 
 15.6% 30.9% 14.9% 1.4% 4.0% 3.5% 0.8% 6.9% 
Blank 2 0 1 0 0 0 0 0 
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Frequency percentages for TNBC stage at diagnosis among the eight groups were 
calculated. Statistically significant differences [X2 (28) = 316.01, p < 0.001] were 
observed among race/ethnicities. NH Black women had the highest frequency for Stages 
III and IV (18.5% and 8% respectively), Hispanic women had the second highest for 
Stage III (17.3%) followed by Filipina women (16.55%). For Stage IV tumors, 
Vietnamese women (5.9%) and Chinese women (5.8%) followed NH Black women. For 
Stage I tumors, NH White women had the highest frequency (38.1%) and least for 
Hispanic women (27.2%) and Asian Indian women had the highest frequency for Stage II 
tumors (49.2%). Cases with unknown tumor stage information was categorized as an 
independent category and it ranged from 0.8% to 5.6% across eight groups. TNBC tumor 
sizes also significantly varied among the eight groups (p < 0.001). The median tumor size 
2.5 centimetres (cms) was the same for NH Black, Hispanic, and Vietnamese women. 
Asian Indian women had 2.45 cms, Filipina women 2.4 cms, Korean women 2.3 cms, and 
Chinese, NH White women had 2.2 cms at the time of diagnosis. 
Significant differences were observed for TNBC tumor histology [X2 (14) = 24.75, p 
= 0.037]. All groups were similar with the ductal classification as the majority. 
Vietnamese women were designated only as ductal carcinoma with no lobular or mixed 
carcinoma classifications. There were 98.3% of Asian Indian women identified to have 
ductal carcinoma histology followed by NH Black at 98%. For lobular type histology, 
frequency ranged from 0% to 2.4% with mixed type ranging from 0% to 1.7%. The 
TNBC tumor grade also showed significant differences for different categories among the 
eight groups [X2 (28) = 170.43, p < 0.001]. Refer to Table 3.4. Like tumor stage, tumor 
106 
 
grade also had an ‘unknown’ grade category frequencies per stage that ranged from 
2.4-7.2%. Korean women had the highest grade IV frequency (2.4%) while Asian Indian 
and Vietnamese women, had no grade IV tumors. However, Asian Indian had the highest 
frequency for grade III tumors (84.7%) followed by Vietnamese and NH Black (81.2% 
and 79.3%, respectively). For grade II tumors, Chinese women had the highest frequency 
followed by Filipina and NH White (23.6%, 21.5%, and 18.5% respectively). 
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Table 3.4 
TNBC Phenotypic Characteristics among Women of Color, *p < 0.001 
Variable
*
 NH White NH Black Hispanic 
(All 
Races) 
Chinese Asian 
Indian 
Filipina Korean Vietnamese 
Tumor Grade         
I 345 
2.4% 
70 
1.5% 
45 
1.6% 
6 
2.2% 
0 
- 
10 
2.8% 
1 
0.8% 
2 
2.4% 
II 2686 
18.5% 
615 
13.2% 
380 
13.6% 
65 
23.6% 
14 
10.7% 
76 
21.5% 
19 
15.1% 
12 
14.1% 
III 10585 
73.0% 
3694 
79.3% 
2171 
78.0% 
184 
66.7% 
111 
84.7% 
248 
70.1% 
96 
76.2% 
69 
81.2% 
IV 141 
1.0% 
32 
0.7% 
45 
1.6% 
1 
0.4% 
0 
- 
6 
1.7% 
3 
2.4% 
0 
- 
Unknown 736 
5.1% 
247 
5.3% 
144 
5.2% 
20 
7.2% 
6 
4.6% 
14 
4.0% 
7 
5.6% 
2 
2.4% 
Lymph node 
involvement 
        
No 9464 
66.4% 
2655 
58.0% 
1598 
58.4% 
178 
65.4% 
77 
59.7% 
215 
62.3% 
72 
60.0% 
56 
65.9% 
Yes 4791 
33.6% 
1923 
42.0% 
1137 
41.6% 
94 
34.6% 
52 
40.3% 
130 
37.7% 
48 
40.0% 
29 
34.1% 
Metastasis         
No 13621 
94.1% 
4281 
92.0% 
2631 
94.7% 
260 
94.2% 
125 
96.2% 
334 
94.9% 
120 
95.2% 
80 
94.1% 
Yes 854 
5.9% 
370 
8.0% 
148 
5.3% 
16 
5.8% 
5 
3.8% 
18 
5.1% 
6 
4.8% 
5 
5.9% 
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When analysing lymph node involvement and metastasis, significant group 
differences were observed among TNBC tumors for lymph node involvement [X2 (7) = 
143.99, p < 0.001] and for metastasis [X2 (7) = 32.94, p < 0.001]. The NH Black, 
Hispanic (All Races), and Asian Indian groups had the highest frequency for positive 
lymph node invasion (42%, 41.6%, and 40.3%, respectively). The NH Black population 
had the highest frequency (8%) for metastasis followed by Vietnamese, NH White 
women (5.9%), and the lowest incidence among the Asian Indian group (3.8%).  
Significant group differences were observed among all three treatment variables: 
chemotherapy [X2 (7) = 104.3, p < 0.001]; radiation [X2 (28) = 118.31, p < 0.001]; and 
surgery [X2 (14) = 79.321, p < 0.001]. Refer Table 3.5. Among TNBC women, Asian 
Indian women had the highest frequency for receiving chemotherapy (85.5%), followed 
by Hispanic (75.5%), NH Black (74.5%), Filipina (73.7%), Vietnamese (71.8%), Korean 
(70.6%), NH White (68.9%) and 66.3% among Chinese. These results should be 
interpreted with caution as SEER collectively provided information about those who did 
not receive chemotherapy along with women who had no information on chemotherapy. 
The range of unknown cases for radiation was 0-1.1% and 0.7-3.5% for surgery.  
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Table 3.5 
Treatment Characteristics among Women of Color, *p < 0.001 
Treatment Variable
*
 NH 
White 
NH Black Hispanic (All 
Races) 
Chinese Asian 
Indian 
Filipina Korean Vietnamese 
Chemotherapy         
Yes 9987 
68.9% 
3472 
74.5% 
2103 
75.5% 
183 
66.3% 
112 
85.5% 
261 
73.7% 
89 
70.6% 
61 
71.8% 
No/Unknown 4506 
31.1% 
1186 
25.5% 
682 
24.5% 
93 
33.7% 
19 
14.5% 
93 
26.3% 
37 
29.4% 
24 
28.2% 
Radiation         
Yes 6712 
46.3% 
2206 
47.4% 
1147 
41.2% 
121 
43.8% 
68 
51.9% 
130 
36.7% 
45 
35.7% 
31 
36.5% 
No 6875 
47.4% 
2100 
45.1% 
1441 
51.7% 
140 
50.7% 
55 
42% 
193 
54.5% 
71 
56.3% 
46 
54.1% 
Recommended, unknown 
if administered 
564 
3.9% 
265 
5.7% 
162 
5.8% 
10 
3.6% 
7 
5.3% 
22 
6.2% 
9 
7.1% 
5 
5.9% 
Refused 237 
1.6% 
56 
1.2% 
26 
0.9% 
4 
1.4% 
1 
0.8% 
5 
1.4% 
0 
3 
3.5% 
Unknown 105 
.7% 
31 
.7% 
9 
.3% 
1 
.4% 
0 
- 
4 
1.1% 
1 
.8% 
0 
- 
Surgery         
Yes 13256 
91.5% 
4094 
87.9% 
2488 
89.3% 
251 
90.9% 
125 
95.4% 
322 
91.0% 
110 
87.3% 
77 
90.6% 
No 1095 
7.6% 
475 
10.2% 
254 
9.1% 
23 
8.3% 
4 
3.1% 
25 
7.1% 
12 
9.5% 
5 
5.9% 
Unknown 142 
1.0% 
89 
1.9% 
43 
1.5% 
2 
0.7% 
2 
1.5% 
7 
2.0% 
4 
3.2% 
3 
3.5% 
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For cases that received radiation, Asian Indian women had the highest frequency 
followed by NH Black and NH White women (51.9%, 47.4%, and 46.3%, respectively). 
Chinese women had a frequency of 43.8%, Hispanic 41.2%, Filipina 36.7%, Vietnamese 
36.5% and Korean 35.7%. For no radiation, the leading groups were Korean (56.3%), 
Filipina (54.5%), and Vietnamese (54.1%). The remaining groups had the following 
percentages: Hispanic (All Races), 51.7%; Chinese, 50.7%; NH White, 47.4%; NH Black, 
45.1% and Asian Indian, 42%. All eight groups included cases who were recommended 
to have radiation therapy (RT), but the information was unknown if they received the RT 
or not. This percentage was highest for Korean (7.1%) and least for Chinese (3.6%). The 
percentage of women who refused to have RT was highest for the Vietnamese (3.5%) and 
lowest for the Korean women with no cases recorded. 
Among eight groups, 95.4% of Asian Indian women underwent surgery and the other 
groups ranged between 87.3%-91.5%. NH Black women had the highest percentage for 
not having a surgery (10.2%), followed by Korean (9.5%) and Hispanic women (9.1%). 
The other five groups not receiving surgery ranged from 3.1% to 8.3%.  
Missing cases were grouped as an individual category and were included only for 
frequency calculation. No data was transformed. Missing data ranged from 0.8% to 5.6%, 
assumed to be missing at random and due to the lower percentage of missing data, 
statistical imputation of values was not performed. 
Discussion 
 Our study is the most recent using a TNBC sample collected from 18 SEER 
Registries for the years 2010 to 2013. The sample included women from three major 
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races/ethnicities (NH White, NH Black, and Hispanic) and five ethnicities (Chinese, 
Asian Indian, Filipina, Vietnamese, and Korean). We reported age-adjusted and 
age-specific incidence rates on NH White, NH Black, Hispanic, and NH Asian Pacific 
Islander. The most recent information in published literature is from cases diagnosed in 
the year 2010 and reported by Howlader et al. (2014). Another study used cases 
diagnosed between 2006 and 2009. The findings of this study are consistent with 
Howlader et al.’ overall ranking of age-adjusted incidence rates (NH Black women with 
the highest, followed by NH White, Hispanics and NH Asian Pacific Islander women) 
(Clarke et al., 2012). However, our study differed in that NH Black women had their peak 
TNBC age-specific incidence rate at a younger age in the age-group 60-64 years followed 
by 65-69 years. Howlader et al. (2014) study reported the peak rate for age-group 65-69 
years old.  
For TNBC age-specific incidence rates, our study found NH Black group highest for 
all 14 age-groups with NH White, Hispanic and NH Asian Pacific Islander groups having 
variable ranking after NH Black. See Table 3.1. Also, there were differences among the 
age-groups where TNBC peaked for each major racial group. Other published studies 
with reported TNBC incidence rates reported only on NH White, NH Black, and Hispanic 
women (Kohler et al., 2015, Plasilova et al., 2016, Amirikia, Bills, Bush & Newman, 
2011). This study results agree with these published studies that NH Black women have 
highest incidence, almost double that of NH White or the Hispanic women and the least 
incidence observed were among the NH Asian Pacific Islander women. Two published 
studies reported on age-adjusted rates were limited by sampling: age restricted to 50-79 
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years (Phipps et al., 2011), ethnicity restricted to White and Black (Lund et al., 2009). 
The disproportionate burden of TNBC among NH Black warrants further research on risk 
factors including, but not limited to genetic mutations, family history, nativity status, age, 
income, education, insurance, reproductive factors (menarche, menopause, parity, breast 
feeding, oral contraceptive pill usage), lifestyle (exercise, smoking, alcohol) and others. 
 In this research study TNBC was found to present as ductal carcinoma, 
consistent with previously published studies (Kanaan et al., 2014; Llanos et al., 2015; 
Orucevic et al., 2015; Plasilova et al., 2016; Swede et al., 2011; Tawfik et al., 2010; Telli 
et al., 2011), and less likely to be lobular or mixed type (Rummel, Varner, Shriver, & 
Ellsworth, 2013; Swede et al., 2011; Tawfik et al., 2010). Also, our study noted, 60-70% 
of the TNBC cases were Stage II and above with the highest percentage among NH 
Blacks, lowest among NH White and other ethnic groups in-between, consistent with the 
published literature (Parise & Caggiano, 2017; Llanos et al.2015; Rummel, Varner, 
Shriver, & Ellsworth, 2013; Brown, Tsodikov, Bauer, Parise, & Caggiano, 2008; Lin et 
al., 2012; Bauer et al., 2007). Our study further affirms previous findings that TNBC 
median tumor size at presentation is significantly greater than 2cms (Santebennur, 
Palanisamy, Gabriel, & Sanmugarajah, 2008; Parise & Caggiano, 2017; Banegas et al., 
2014; Sineshaw et al., 2014; Plasilova et al., 2016; Llanos et al., 2015; Kanaan et al., 
2014). The incidence of TNBC grade III tumors in our study, 67.1 % to 84.7 %, was also 
found to be similar to that found in other studies like previously published in literature 
(Plasilova et al.2016; Parise & Caggiano, 2017; Sineshaw et al, 2014; Llanos et al., 2015; 
Banegas et al., 2014; Tawfik et al, 2010; Orucevic et al., 2015; Kanaan et al., 2014; 
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Rummel et al., 2013; Zaky et al., 2011). Our study reports findings on metastasis 
consistent with Zaky et al. that NH Black women have the highest frequency. For 
positive lymphovascular invasion among TNBC cases, our study provides statistical 
significant (p < 0.001) information for eight race/ethnicities. Studies had previously 
reported on only Hispanic women (Banegas et al., 2014), or African American and 
Caucasian women (Tawfik et al., 2010) and only non-significant (p = 0.856) differences 
among African American and Caucasian TNBC women (Sturtz et al., 2014).  
 Significant phenotypic differences among the eight groups were observed in our 
study. Our study provides further evidence of the association between TNBC and median 
age at diagnosis. Consistent with previous findings, NH Black women were found to be 
diagnosed at a younger age compared to other ethnic groups (Sullivan et al., 2014). Our 
study is the first to report statistically significant differences between ethnic groups for 
TNBC stage, tumor grade, tumor histology, tumor size, lymph node involvement, 
metastasis, and treatment (for all p < 0.001, except histology, p = 0.037). 
 Non-significant ethnic differences have been reported by (Sullivan et al., 2014; 
Pacheco et al., 2013; Chu, Henderson, Ampil & Li, 2012; Dawood et al. 2009; Iqbal et al. 
2015; Sturtz et al., 2014). Smaller sample sizes (Chu, Henderson, Ampil & Li, 2012; 
Sturtz et al., 2014), sampling restricted to one type of patient treatment (Dawood et al., 
2009), or early stages of cancer (Chu et al., 2012), smaller tumor sizes (Iqbal et al., 2015), 
or an individual clinic sample (Pacheco et al., 2013) could be reasons for the 
non-significance findings in these studies. Studies that examined TNBC phenotypic 
differences among ethnicities focused predominantly on African American and Caucasian 
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women. Our study is the first study to analyze five individual Asian sub-groups as well as 
Hispanic women in addition to the major races, NH Black and NH White. 
 This study is the first to provide the TNBC incidence rates on major races in the 
U. S. for the most recent years (2010-2013) and to illustrate the TNBC phenotypic 
differences among ethnicities. Still one of the limitations of our study is the lack of 
population count for the five Asian origin ethnicities: Chinese, Asian Indian, Filipina, 
Korean and Vietnamese, to calculate the respective incidence rates. This lack of 
information prevents us from identifying the TNBC burden among those women. Of note, 
SEER does have pertinent information on clinical and pathological data for all TNBC 
cases which allowed us to highlight the racial/ethnic differences for TNBC risk. Another 
limitation is the lack of detailed information on chemotherapy and hormone therapy on 
all cases. Currently SEER is undertaking efforts to provide more information on 
chemotherapy details of patient. 
 Limitations encountered in this study included the lack of population count for the 
five Asian ethnicities. A second limitation was the incomplete information in the SEER 
registry on hormone therapy, chemotherapy and a lack of information on nativity status. 
SEER is currently undertaking efforts to provide information on these variables.  
In summary, TNBC clinically presents as a tumor with larger diameters, 
predominantly as ductal carcinoma, higher grade, later stage at presentation, and in 
younger age groups of NH White, NH Black, Hispanic, Chinese, Asian Indian, Filipina, 
Korean and Vietnamese women. Significant ethnic differences were noted for the TNBC 
phenotype and NH Black women along with the few Asian sub-groups, to have higher 
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TNBC burden compared to NH White women. Additional research examining the risk 
factors in association with TNBC and TNBC phenotype differences among diverse 
sample population is needed to confirm our study findings and to enhance measures to 
decrease the TNBC impact on the lives of these women.   
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CHAPTER 4 
RISK FACTORS ASSOCIATED WITH THE TRIPLE-NEGATIVE BREAST 
CANCER SUBTYPE AMONG EIGHT RACE/ETHNIC GROUPS AND MODEL 
PREDICTION  
Introduction 
Breast cancer (BC) is one of the common cancer types diagnosed in women with 
a high frequency in the United States (U.S.). The American Cancer Society (2017) 
estimated 252,710 new female breast cancer cases with an estimated 40,610 deaths for 
the year 2017 (Cancer Facts and Figures, 2017). The overall breast cancer incidence rate 
(2009-2013) remains as 123.3 (per 100,000 age adjusted to the 2000 U. S. standard 
population) reported by North American Association of Central Cancer Registries (Siegel, 
Miller, & Jemal, 2017).    
Although the death rate has declined since 2000 and reached its lowest level for 
the years 2010-2014 as 21.2 (per 100,000 age adjusted to 2000 U. S. standard population), 
the death rates vary between race/ethnicities and BC subtypes. Non-Hispanic Black 
women lead with a death rate of 30 followed by Non-Hispanic White women (21.1), 
Hispanic women (14.4) and least among Asian and Pacific Islander women (11.3), all 
rates per 100,000 age adjusted to 2000 U.S. standard population (Mortality Statistics, 
2010-2014). Intrinsic breast cancer subtypes from the St. Gallen 2011 Consensus has four 
subtypes: Luminal A, Luminal B, Erb-B2 overexpression, and Basal-like (surrogate 
definition is Triple Negative Breast Cancer [TNBC]). Women with TNBC were twice as 
likely to die from the disease compared to all other BC subtypes (p < 0.0001) (Matt, 
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Mozayen, Gress, & Tirona, 2015). Even among TNBC cases, African American women 
with Stage III TNBC had a higher risk of breast cancer death compared to White women 
(n=103,498), even after adjusting for tumor characteristics, first course of treatment, 
neighborhood socio economic status and insurance status (Tao, Gomez, Keegan, Kurian, 
& Clarke, 2015). Hispanic women with TNBC data recorded in the California Cancer 
Registry was used by Banegas et al. (2014) to report a poorer survival compared to 
HR+/HER2- tumors.  
The breast cancer sub-types Luminal A, Luminal B, and Erb-B2 overexpression 
can be grouped as Non-TNBC cases and compared with TNBC (basal-like). TNBC 
patients compared to Non-TNBC patients had 50% increased risk for all-cause mortality 
and even after covariate adjustment TNBC was associated with non-Breast Cancer 
mortality such as circulatory system diseases, other cancers or causes (HR = 2.15) and 
Breast Cancer-mortality (HR = 1.42) (Lian et al., 2014). Studies on ethnic differences in 
TNBC cases predominantly concentrated on White, Black, Hispanic women population, 
and Asians grouped as Asian Pacific Islander (Parise and Caggiano, 2017; Plasilova et al., 
2016; Sineshaw et al., 2014). Also, studies were primarily single institution or single 
registry studies (Parise and Caggiano, 2017; Llanos et al., 2015; Sullivan et al., 2014; 
Sturtz et al., 2014; Banegas et al., 2014; Pacheco et al., 2013; Tawfik et al., 2010; Chu et al., 
2012; Swede et al., 2011).  
Purpose of the Study 
The research question and hypotheses related to the problem of interest are: 
Question and Research hypothesis 
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a) What are the variables that are associated with TNBC compared to non-TNBC 
among the eight groups? 
Race/ethnicity, age at diagnosis, tumor histology, tumor size, tumor grade, tumor stage, 
lymph node invasion, metastasis, and treatment (radiation, surgery, chemotherapy) will 
be associated with TNBC. 
Question and Research hypothesis 
b) Will there be higher/lesser odds for any race/ethnic group to develop TNBC 
compared to Non-Hispanic White women? 
Non-Hispanic Black, Hispanic (All Races), Korean, Asian Indian women will have 
significantly higher odds for TNBC compared to Non-Hispanic White women and Chinese, 
Filipina, Vietnamese women will have lower odds compared to Non-Hispanic White 
women. 
Question and Research Hypothesis 
c) What are the predictors for TNBC compared to Non-TNBC among the eight ethnic 
groups? 
Race/ethnicity, age at diagnosis, tumor grade and tumor stage will significantly predict 
the risk for developing TNBC among the eight races/ethnicities. 
Hence the purpose of the study was to identify potential predictive factors (age at 
diagnosis, race/ethnicity, education, income, SES, insurance status, nativity) for TNBC 
among women of color using a large sample database. Also, to assess the odds for 
race/ethnic groups (Non-Hispanic Black, Non-Hispanic White, Hispanics, Asian Indian, 
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Chinese, Filipina, Vietnamese, and Korean women) to develop TNBC compared to 
Non-Hispanic White women.  
Methods 
Data from the 18 SEER cancer registries was used to identify women diagnosed with 
primary invasive breast cancer during the years 2010-2013. The 18 cancer registries 
included in the study serve Alaska Native Tumor Registry, Atlanta, Connecticut, Detroit, 
Hawaii, Iowa, Greater California, Rural Georgia, Greater Georgia, Kentucky, Louisiana, 
Los Angeles, New Mexico, New Jersey, San Francisco-Oakland, San Jose-Monterey, 
Seattle-Puget Sound, and Utah. The SEER population is comparable to the general 
United States (U. S.) population in regards to poverty and education. The proportion of 
foreign-born persons is higher among SEER compared to the general U. S. population 
(Population Characteristics, 2017). Although SEER does not indicate rationale for the 
higher levels of foreign-born population when compared to the U. S. general population, 
it is possible that this may be due to the higher frequency of Asian immigrants in those 
areas covered by SEER Registries. All study related data was obtained from SEER 
database after signing a Research Data Agreement for internet data access. SEER*Stat 
software Version 8.3.2 was used for data collection and analysis 
(www.seer.cancer.gov/seerstat). The SEER Research data used for the study was from 
November 2015 submission. Exempt review approval from Clemson University 
Institutional Review Board was obtained.   
From the SEER database, all women age 18 years and older with their self-identified 
race/ethnicity recorded as Non-Hispanic White, Non-Hispanic Black, Hispanic, Chinese, 
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Asian Indian, Korean, Vietnamese, and Filipina, were selected for the study. The 
Hispanic women in this study includes Hispanics from all races. For the variable, Breast 
Subtype (2010+), ‘Triple Negative’ category was selected for the TNBC group and breast 
cancer subtypes ‘Her2+/HR+’, ‘Her2+/HR-’, ‘Her2-/HR+’ were collectively grouped as 
Non-TNBC women. The above-mentioned BC subtypes as noted by SEER are noted 
elsewhere as HR+/Her2+, HR+/Her2-, HR-/Her2+. The investigators used SEER*Stat to 
create a case listing for primary TNBC and Non-TNBC female malignant cases from all 
18 registries. Other variable information that were extracted included: race/ethnicity, age 
at diagnosis, insurance, median household income (in tens) from the American 
Community Survey (ACS) 2010-2014, the American Joint Committee on Cancer/AJCC 
for stage, size of tumor, tumor histology, tumor grade, lymph node involvement, 
metastasis, and treatment (chemotherapy, radiation, surgery). For median household 
income level, SEER reports the dollars in number values which needs to be multiplied by 
10 to get the original income in dollars. 
Data extracted from SEER database was saved as a raw file in SPSS. Total TNBC 
case information that was extracted for the raw file was 22,909. Similarly, for 
Non-TNBC, the raw file extracted 171,733 cases. After exclusion of two cases due to age 
less than 18 years, one in each group, 22,908 cases from TNBC and 171,732 from 
Non-TNBC (total sample number of 194,640 women) were included in data analysis. 
Median age at diagnosis was calculated for both groups. Women who were classified as 
85+ years were coded as 85 (using Microsoft excel) and median age was calculated for 
study sample using SPSS. Women were grouped into two age categories: less than 40 
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years and more than 40 years and included in analysis. Forty years was used as a cut-off 
for age group categories as breast cancer screening for women start at the age of forty. 
SEER provides information on insurance status of the women at the time of diagnosis. 
They are entered as “uninsured, any Medicaid, insured, insured/no specifics, insurance 
status unknown.” 
SEER also provides county attributes that were taken from American Community 
Survey 2010-2014. They include Median household income in the past 12 months (in 
2015 inflation-adjusted dollars) and the percent of persons whose income were below 
poverty level of the U. S. in the past 12 months. The American Community Survey 
County attributes were obtained along with other variable information. SEER database 
already has the information on median household income and persons below poverty 
percent directly linked to each SEER case. Median household income is provided in tens 
ranging from $1915 to $12397. Percent of persons below poverty is provided in a range 
from 1.04% to 52.63%. The above two variables were categorized into different levels for 
the given range. Those cases with less than 10% for poverty percent were categorized as 
high Socio Economic Status (SES), 10-19.9% for medium SES and greater than 20% for 
low SES. Using the county attribute of “percentage of persons living below the US 
poverty line” has proven to be the best measure to assess SES (Krieger et al., 2002).  
The AJCC Stage was coded for data analysis as: stages IA and IB coded as I, stages 
IIA, IIB as stage II, stages IIIA, IIIB, IIIC, IIINOS as stage III, and Stage IV remained 
the same. There were 52 cases at Stage 0 and were excluded from analysis. For other 
variables: 1) Tumor Histology: SEER codes used- 8500/3: Infiltrating duct carcinoma, 
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NOS, 8520/3: Lobular carcinoma, NOS, 8522/3: Infiltrating duct and lobular carcinoma 
and the rest were categorized as “others.” There were 3,156 TNBC cases with histology 
of “other” categories and these were excluded from analysis. Tumor Grade: “Well 
differentiated; Grade I” coded as Grade I, “Moderately differentiated; Grade II” as Grade 
II, “Poorly differentiated; Grade III” as Grade III and “Undifferentiated; anaplastic; 
Grade IV” as Grade IV. Unknown cases were classified as a separate category in tumor 
stage and tumor grade. 
SEER has tumor size entered in numeric value (millimetres) and some cases has 
information as “values under review”, “no primary tumor found, no Paget’s disease”, 
“microscopic focus of foci only”, “mammography/xerography diagnosis with no size 
given”, “diffuse”, “unknown”, “3 mm or less than 3mm”, “Paget disease of nipple with 
no demonstrable tumor.” Median tumor size was calculated for the eight race/ethnic 
groups. The only category other than direct numerical values that was included in 
calculation was “3 mm or less than 3mm” and it was coded as <3mm. All other 
categories mentioned above were not included in median tumor size calculation. 
Microsoft excel was used to convert the string values to numerical values (example: 
20mm converted 20) and then SPSS was used to calculate median tumor sizes. Lymph 
node involvement was categorized as yes and no. All cases that had a N1, N1a, N1b, N1c, 
N1mi, N1NOS, N2, N2a, N2b, N2NOS or N3, N3a, N3b, N3c, N3NOS was coded as 
“yes” and those with N0, N0(i-), N0(i+), N0(mol-), N0(mol+) was a “no.” 2716 cases had 
a NX (lymph nodes cannot be evaluated) and were excluded from the analysis, but not 
the 39 cases with NA (Not Applicable) which was categorized separately. Similarly, there 
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were 39 cases that had an NA for metastasis and they were excluded from regression 
analysis. M0 and M0 (i+) were grouped as “no” and M1 as “yes.”  
The three variables under treatment are Chemotherapy, Surgery, and Radiation. 
SEER does not have hormone therapy information on all data in the November 2015 
submission. SEER is currently collecting hormone therapy information as part of 
treatment data for cancer cases. An additional agreement was signed before access was 
obtained for chemotherapy information on all study cases. The rationale is discussed 
under study limitations. The database we used was Incidence-SEER 18 Regs Custom 
Data (with chemotherapy recode), Nov 2015 Sub (2000-2013) identical to Incidence- 
SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 
Sub (2000-2013). “Yes” for chemotherapy indicates that patient had chemotherapy as 
part of first line of treatment and “no” indicates chemotherapy not given or unknown 
(SEER*Stat Technical support, personal communication, August 5 2016). Noone et al. 
(2016) reported an overall 68% of sensitivity for SEER chemotherapy information, but 
high specificity which means that if chemotherapy information is given in SEER then it 
was most likely received by the patient. 
Radiation information in SEER was coded into five categories: a) beam radiation, 
combination of beam with implants or isotopes, radiation, NOS method of source not 
specified, radioactive implants, radioisotopes (coded as “yes’), b) none (“no”), c) 
recommended, unknown if administered, d) unknown, and e) refused. Surgery coded into 
four categories as follows: a) surgery performed as “yes”, b)recommended but not 
performed, patient refused/ recommended but not performed, unknown reason as 
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“refused”, c) not recommended, contraindicated due to other cond; autopsy only 
(1973-2002)/ not performed, patient died prior to recommended surgery/ not 
recommended as “no”, and d) unknown; death certificate; or autopsy only (2003+)/ 
recommended, unknown if performed as “unknown.” Missing cases were categorized as 
an individual level and was included only for frequency calculation (see Table 4.3 and 
Table 4.4) Missing cases at random were excluded from regression analysis. No data was 
transformed. 
Statistical Analyses 
Statistical software SPSS version 24 was used for comparing TNBC and Non-TNBC 
clinico-pathologic characteristics. Chi-square tests were employed to compare frequency 
distributions between the two groups for clinico-pathologic characteristics: age at 
diagnosis (<40> years), race/ethnicity, tumor histology, tumor grade, tumor stage, lymph 
node involvement, metastasis, and treatment (chemotherapy, radiation, surgery). A 
Binary Logistic Regression model was used to calculate beta coefficients, Odds Ratios 
(ORs) and 95% confidence intervals to quantify associations between various predictors 
and TNBC/non-TNBC group. For model prediction, the total sample number was 
160,423 including TNBC and non-TNBC cases, which is after excluding cases 
categorized as “Others” for histology (20,363), unknown tumor stage and stage 0 (3,382), 
unknown tumor grade (6,328), unknown insurance status (2,257), unknown radiation 
(777), missing poverty percent (18 women with the same cases missing median 
household income information as well), and unknown information for surgery (1,092). 
Four models were constructed for predicting TNBC group membership using statistically 
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significant variables. Model 1 was an unadjusted model for TNBC/non-TNBC and 
race/ethnicity. Model 2 adjusted for all predictors and included race/ethnicity, age groups 
(less than and greater than 40 years), insurance status, median Household income, percent 
below poverty, tumor histology, tumor grade, tumor stage, surgery, and radiation. Tumor 
size, lymph node involvement, and metastasis was not included as they are part of tumor 
stage variable information. Model 3 was again an adjusted model with only variables that 
contributed significantly to the model. Model 4 was an adjusted model with interaction 
effects between predictor variables. P value of less than equal to 0.05 was considered 
statistically significant. 
Results 
For the years 2010-2013, the 18 SEER registries had data on 171,732 Non-TNBC 
cases and 22,908 women whose primary breast cancer diagnosis was TNBC, aged 18 
years and above. TNBC proportions among Non-Hispanic White, Non-Hispanic Black, 
Hispanic, Chinese, Asian Indian, Korean, Vietnamese, and Filipina women were 
calculated. Among all cases (TNBC and Non-TNBC cases), NH Black had the highest 
frequency (21.25%) for TNBC followed by Asian Indian (12.96%), Hispanic (12.69%), 
Korean (12.1%), NH White (10.3%), Chinese (9.38%), Vietnamese (9.1%), and Filipino 
(8.44%). See Figure 4.1.  
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Figure 4.1 
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Statistically significant [X2 (7) = 2276, p < 0.001] differences were observed for 
frequency of the eight races/ethnicities between the TNBC and non-TNBC groups. 
Compared to non-TNBC group, the proportion of NH White, Chinese, and Vietnamese 
women was less in TNBC. However, for NH Blacks the frequency for TNBC women was 
twice that of Non-TNBC (20.3% versus 10% respectively). Similarly, Hispanic, Filipino, 
Asian Indian and Korean women had greater frequency of TNBC than non-TNBC.  
Median age at diagnosis was calculated for TNBC and non-TNBC groups. See Table 
4.1. Statistical significance (p < .001) was obtained for the differences in median age at 
diagnosis which was 62 years among non-TNBC and 58 years among TNBC women. For 
women, less than 40 years of age, statistically significant higher frequency observed for 
TNBC group when compared to non-TNBC group (p < .001; 9.9% versus 5.4% 
respectively).  
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Table 4.1 
Comparison of Demographic Characteristics between TNBC 
 and non-TNBC Cases, *p < 0.001 
 
Variable* Non-TNBC 
Count 
% 
TNBC Count 
% 
Median age at 
diagnosis, years 
62 58 
Age groups   
< 40 years 9325 
5.4% 
2268 
9.9% 
> 40 years 162407 
94.6% 
20640 
90.1% 
Race/Ethnicity 
(N=194,640) 
  
Non-Hispanic 
White 
126158 
73.5% 
14493 
63.3% 
Non-Hispanic 
Black 
17258 
10.0% 
4658 
20.3% 
Hispanic (All 
Races) 
19165 
11.2% 
2785 
12.2% 
Chinese 2665 
1.6% 
276 
1.2% 
Filipino 3842 
2.2% 
354 
1.5% 
Vietnamese 849 
0.5% 
85 
0.4% 
Asian Indian 880 
0.5% 
131 
0.6% 
Korean 915 
0.5% 
126 
0.6% 
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Table 4.1 continued 
Variable* Non-TNBC Count  
% 
TNBC Count % 
Persons below poverty 
Percent (n=194,640) 
  
1.04-9.99% 27317 
15.9% 
3070 
13.4% 
10-19.99% 120018 
69.9% 
15690 
68.5% 
20-52.63% 24355 
14.2% 
4145 
18.1% 
Blank 42 
- 
3 
- 
Insurance Status 
(n=194,640) 
  
Uninsured 3047 
1.8% 
619 
2.7% 
Insured 124011 
72.2% 
15603 
68.1% 
Any Medicaid 18726 
10.9% 
3310 
14.4% 
Insured/No specifics 22982 
13.4% 
3014 
13.2% 
Insurance status unknown 2966 
1.7% 
362 
1.6% 
Median Household 
Income (in tens) (N=194,595) 
  
1915-3999 10729 
6.2% 
1905 
8.3% 
4000-4999 30135 
17.6% 
4647 
20.3% 
5000-5999 52487 
30.6% 
7187 
31.4% 
6000-6999 34265 
20.0% 
4216 
18.4% 
7000-7999 26868 
15.6% 
3126 
13.6% 
8000-8999 8892 
5.2% 
976 
4.3% 
9000-9999 7115 
4.1% 
725 
3.2% 
10000-12397 1199 
0.7% 
123 
0.5% 
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Statistically significant differences [X2 (4) = 367.42, p < 0.001] exist for insurance 
status at the time of diagnosis between the two groups. Percentage of women in uninsured 
category is higher for TNBC group compared to non-TNBC (p < .001; 2.7% versus 1.8% 
respectively). Presence of any Medicaid at the time of diagnosis was in higher 
proportions for TNBC compared to non-TNBC group. Percentage of women insured was 
higher for non-TNBC group compared to TNBC group (72.2% versus 68.1%).  
Statistically significant differences were observed between TNBC and non-TNBC 
groups when assessed for county attribute variables such as persons below poverty 
percent, an attribute found in the American Community Survey. Statistical significant [X2 
(3) = 299.3, p < 0.001] differences exist between the two groups for persons below 
poverty percent. Among breast cancer women who belong to 20-56.3% below poverty 
percent (low SES), higher frequency observed for TNBC versus non-TNBC group (18.1% 
versus 14.2% respectively) For levels less than 9.99% (high SES) and 10-19.99% 
(medium SES), TNBC group ranked lesser in frequency compared to Non-TNBC group. 
Median household income which is another county attribute showed significant [X2 (7) = 
388.54, p < 0.001] differences between groups. Higher proportions observed for TNBC 
for levels from $1915 to $5999 (in tens) and lower proportions from $6000 to 12397 (in 
tens) when compared to non-TNBC group.  
 
 
 
 
137 
 
Table 4.2 
Comparison of Phenotypic Characteristics between TNBC and non-TNBC 
*p < 0.001 
 
Variable* Non-TNBC 
% 
TNBC 
% 
Stage At Diagnosis   
I 87292 
50.8% 
7878 
34.4% 
II 53696 
31.3% 
9562 
41.7% 
III 18739 
10.9% 
3499 
15.3% 
IV 8517 
5.0% 
1422 
6.2% 
NA 5 
0.0% 
34 
0.1% 
Unknown Stage 3435 
2.0% 
509 
2.2% 
Tumor size 
(median, cms) 
1.70 2.0 
<2cms 90471 
54.7% 
12627 
47.7% 
2-5cms 55704 
33.7% 
10081 
38.0% 
>5 cms 13961 
8.4% 
2972 
11.2% 
Unknown 5269 
3.2% 
816 
3.1% 
Tumor Histology 
Ductal 
126213 
81.7% 
19163 
97.0% 
Lobular 17695 
11.5% 
291 
1.5% 
Mixed 10617 
6.9% 
298 
1.5% 
Tumor Grade 
 I 
41574 
24.2% 
479 
2.1% 
II 77448 
45.1% 
3867 
16.9% 
III 43984 
25.6% 
17158 
74.9% 
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IV 
Table 4.2 continued 
 
502 
0.3% 
 
 
228 
1.0% 
Unknown 8224 
4.8% 
1176 
5.1% 
Lymph node 
involvement 
  
No 114320 
67.5% 
14315 
63.5% 
Yes 55046 
32.5% 
8204 
36.4% 
Not Applicable 5 
- 
34 
0.2% 
Metastasis   
No 163210 
95.0% 
21452 
93.8% 
Yes 8517 
5.0% 
1422 
6.2% 
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Statistically significant (p < 0.05) differences were observed between TNBC and 
Non-TNBC groups when clinico-pathologic characteristics were assessed (refer Table 
4.2). For stage of cancer [X2 (5) = 2416.1, p < 0.001], approximately two-thirds of TNBC 
cases were frequently observed in stages II and above compared to only 50% among 
non-TNBC cases. For stages III and IV, 15.3% and 6.2% were TNBC cases compared to 
10.9 % and 5.0% among non-TNBC cases. Tumor sizes were categorized as < 2cms, 
2-5cms and >5cms with 49.2% of TNBC cases found to be 2cms and above compared to 
42.1% among Non-TNBC cases. TNBC median tumor size was found to be statistically 
significantly [X2 (3) = 538.22, p < 0.001] larger than non-TNBC tumors (2 cms versus 1.7 
cms respectively). Statistically significant differences were observed between TNBC and 
non-TNBC groups for tumor histology [X2 (2) = 2987.52, p < 0.001]. Almost all TNBC 
cases were infiltrating ductal carcinoma (97%) compared to 81.7% among non-TNBC 
cases. For tumor histology, as mixed type (infiltrating ductal and lobular carcinoma), 6.9% 
cases among Non-TNBC cases compared to only 1.5% among TNBC cases. Similarly, 
high proportions of non-TNBC cases were observed to be lobular carcinoma compared to 
1.5% among TNBC cases.   
Statistically significant differences were observed between TNBC and non-TNBC 
groups for tumor grade [X2 (4) = 24330.39, p < 0.001], lymph node involvement [X2 (2) = 
352.8, p < 0.001] and metastasis [X2 (1) = 65.81, p < 0.001]. Approximately 75.9% of 
TNBC cases were observed to be tumor grades III and above compared to only 25.9% of 
cases among non-TNBC cases. Many non-TNBC cases were Grade II, moderately 
differentiated (45.1%) whereas most TNBC cases (74.9%) were Grade III, poorly 
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differentiated. For lymph node involvement, 36.4% of TNBC cases versus 32.5% of 
non-TNBC were positive. Similarly, a higher percentage of TNBC cases had positive 
metastasis compared to non-TNBC cases (6.2% versus 5% respectively). There also were 
statistically significant differences noted for treatment variables such as surgery [X2 (3) = 
95.42, p < 0.001], chemotherapy [X2 (1) = 9903.38, p < 0.001], and radiation [X2 (4) = 
177.79, p < 0.001] between TNBC and Non-TNBC groups. For surgical treatment, 
slightly higher proportions were observed among Non-TNBC cases (91.9% versus 90.5% 
among TNBC cases). Almost twice the number of TNBC cases received chemotherapy 
compared to Non-TNBC cases (71% versus 36.6% respectively) and higher percentage of 
Non-TNBC cases compared to TNBC cases did not receive chemotherapy or 
chemotherapy information is unknown (63.4% versus 29% respectively). For treatment 
(refer to Table 4.3), 49.4% of Non-TNBC cases and 45.7% of TNBC cases received 
radiation; 1.8% of Non-TNBC cases and 1.5% of TNBC cases refused radiation treatment. 
Tumor stage, size, grade had unknown cases and lymph node invasion status included 
‘not applicable’ cases and their frequency for each group can be seen in Table 4.2. 
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Table 4.3 
Treatment Characteristics, TNBC vs non-TNBC 
*p < 0.001 
 
Variable* Non-TNBC Count 
 % 
TNBC Count 
 % 
Treatment   
Surgery   
Yes 157900 
91.9% 
20723 
90.5% 
No 10671 
6.2% 
1674 
7.3% 
Refused 1775 
1.0% 
219 
1.0% 
Unknown 1386 
0.8% 
292 
1.3% 
Chemotherapy   
No/Unknown 108828 
63.4% 
6640 
29.0% 
Yes 62904 
36.6% 
16268 
71.0% 
Radiation   
Yes 84791 
49.4% 
10460 
45.7% 
No 76836 
44.7% 
10921 
47.7% 
Recommended, 
unknown if 
administered 
5933 
3.5% 
1044 
4.6% 
Refused 3079 
1.8% 
332 
1.4% 
Unknown 1093 
0.6% 
151 
0.7% 
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Only the significant (p < 0.05) results from the logistic regression are summarized 
in Table 4.4. Non-TNBC was the reference outcome and NH White women was the 
reference race category. NH Black women followed by Hispanic women were 
significantly more likely to be diagnosed with TNBC (NH Blacks: OR = 2.42, 95% C.I. = 
1.63-3.59; Hispanics: OR = 1.72, 95% C.I.=1.12-2.66). Non-significant higher odds were 
observed for the TNBC group of Filipino (p = 0.40) and Vietnamese women (p = 0.36) 
and non-significant lower odds for Chinese (p = 0.38), Korean (p = 0.83) and Asian 
Indian women (p = 0.99). Women older than 40 years of age were found to have 
significant (p < 0.001) lesser odds (OR = 0.91, 95% C.I.=0.84-0.98) of developing TNBC 
compared to women less than 40 years of age. Women whose median household income 
is less than $5000 (in tens) were at significantly (p = 0.001) higher odds for TNBC 
compared to women income more than $5000 (in tens) (OR = 0.93, 95% C.I.=0.88-0.97) 
and compared to insured women, uninsured women are significantly (p = 0.01) more 
likely to be in TNBC group (OR = 1.16, 95% C.I.=1.04-1.30).  
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Table 4.4 
Significant Predictors for TNBC Risk with OR (95% C. I.)  
Variable B Wald 
Statistic 
P value Exp (B) with  
95% C.I. 
Non-Hispanic 
Black 
0.884 19.369 0.000 2.419 (1.632-3.586) 
Hispanic 0.544 6.028 0.014 1.722 (1.116-2.658) 
Age 
> 40 years 
-0.099 6.063 0.014 0.906 (.838-.980) 
Hispanic * >40 
years of age 
-0.183 5.694 0.017 0.833 (.716-.968) 
Asian Indian 
* >40 years of age 
-0.523 3.892 0.049 0.593 (.353-.997) 
NH Black 0.884 19.369 <.00001 2.419 (1.632-3.586) 
Median 
Household 
$5000-7999 (in 
tens) 
-0.078 10.298 0.001 0.925(.882-.970) 
Histology (lobular 
type) 
-1.484 355.829 <.00001 0.227 (.194-.265) 
Histology (Mixed 
type) 
-1.269 285.372 <.00001 0.281 (.243-.326) 
Insurance (none) 0.150 6.550 0.010 1.162 (1.036-1.303) 
Stage IV -0.197 15.467 <.0001 0.821 (.744-.906) 
Grade IV 3.756 677.843 <.000001 42.770 (32.236-56.745) 
Grade III 3.697 2715.928 <.000001 40.339 (35.102-46.357) 
Grade II 1.717 557.572 <.000001 5.569 (4.829-6.422) 
Radiation None 0.095 18.680 <.00001 1.099 (1.053-1.148) 
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Table 4.4 continued 
NH Black*Stage 
III 
0.144 4.307 0.038 1.155 (1.008-1.323) 
NH Black * 
Grade III 
-0.444 6.624 0.010 0.641 (.457-.900) 
NH Black * 
Median 
household 
$5000-7999 
-0.127 6.851 0.009 0.881 (.801-.969) 
Hispanic* Grade 
II 
-0.422 4.814 0.028 0.656 (.450-.956) 
Hispanic* Grade 
III 
-0.381 4.202 0.04 0.683 (.474-.983) 
Chinese * Stage 
IV 
0.827 4.917 0.027 2.286 (1.101-4.747) 
Chinese * Median 
household 
$ 8000-12397 
1.511 4.053 0.044 4.531.041-19.724) 
Note: * - Interaction effect 
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TNBC women were significantly (p < .00001) more likely to be ductal carcinoma 
compared to lobular or mixed subtype (OR = 0.23, 0.28 respectively). TNBC women 
were at significantly higher odds (p < .0001) to be stage I compared to Stage IV (OR = 
0.821, 95% C.I. = 0.74-0.91) and TNBC women were non-significantly (p = 0.53) more 
likely to be stage II and less likely to be Stage III (p = 0.11). TNBC women were 5.57, 40, 
and 42 times significantly (p < 0.0001) more likely to be Grade II, III, and IV 
respectively when compared to Grade I. Compared to receiving radiation, TNBC women 
were significantly (p < 0.0001) more likely to receive no radiation (OR = 1.1, 95% C.I. = 
1.05-1.15). 
Based on interaction effects, Hispanic women less than 40 years of age were at 
significantly higher odds for TNBC (p = 0.017) and Asian Indian women less than 40 
years of age were at significant higher odds for TNBC compared to NH White women of 
the same age group (p = 0.049). NH Black and Hispanic women were significantly (p = 
0.010, 0.040 respectively) at lesser odds for Grade III compared to Grade I TNBC tumors 
compared to NH White women. NH Black are significantly (p = 0.038) at higher odds for 
Stage III compared to Stage I TNBC tumors compared to NH White women. Hispanic 
women were significantly 2.3 times more likely for Stage IV compared to Stage I TNBC 
tumors compared to NH White women (p = 0.027). Among women who did not receive 
radiation, NH Black women were significantly less (p = .038) likely than NH White to be 
in TNBC group.  
Similar interaction effects were observed between ethnicity and income level. 
Chinese women with median household income $8,000-12,397 (in tens) are 4.5 times 
146 
 
more significantly (p = 0.044) likely to be TNBC versus NH White women of same 
median household income level. NH Black women with income <$5000 (in tens) are at 
significant (p = 0.009) higher odds for TNBC versus NH White women of same median 
household income level. Stage III NH Black women are significantly (p = 0.038) at 
higher odds for TNBC and Stage IV Chinese women are significantly 2.3 times (p = 
0.027) more likely for TNBC compared to Stage I NH women. Persons below poverty 
percent and surgery are non-significant (p > 0.05) predictors and was not included in the 
final adjusted model.  
Discussion 
The findings from this study are consistent with previous studies showing that NH 
Black women have the highest frequency for TNBC (Parise & Caggiano, 2014; Parise & 
Caggiano, 2013; Howlader et al., 2014; Iqbal, Ginsburg, Rochon, Sun, & Narod, 2015; 
Tao et al., 2015; Swede et al., 2011; Morris et al., 2007; Lund et al., 2010) followed by 
Asian Indian, Hispanic, and Korean women (Plasilova et al., 2016). Additionally, we 
reported the following order: for TNBC frequency Korean, NH White, Chinese, 
Vietnamese and Filipino women, whereas Plasilova et al. study published Chinese 
women with higher TNBC frequency than White women. Consistent with other previous 
findings (Parise & Caggiano, 2016), Filipino women were the least likely to have a 
TNBC diagnosis. Although women from the Indian subcontinent (Asian Indian, Pakistani, 
Bangladeshi, Nepalese, Sikkimese, and Sri Lankan) were reported to have the highest 
frequency in several studies (Parise & Caggiano, 2014; Parise & Caggiano, 2016; Telli et 
al., 2011) while this study found Asian Indian women to have highest frequency after NH 
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Black women. Our study also identified that Hispanic women have a higher frequency 
than NH White, but a major difference was reported by Boone et al. (2014). Our study 
provided further evidence of the need to explore the TNBC burden on the individual 
ethnicities, separately. 
Consistent with previous research (Banegas et al., 2014), our study reported 
higher percentages of TNBC women in low and medium SES based on percentage of 
persons below poverty which is a county attribute when compared to Non-TNBC cases. 
Future studies need to explore below poverty percentages as a measure for SES and 
confirm findings from this study. In contrast to published literature, this study reported 
significant associations of TNBC with insurance status and median household income 
and reported significant differences between TNBC and non-TNBC groups for those two 
variables. Only non-significant associations between TNBC and insurance status had 
been previously reported in the literature (Llanos et al.; Telli et al.; Trivers et al. 2009; 
Banegas et al.) and non-significant differences between TNBC and income level (Llanos 
et al.,2015; Dolle et al., 2009).  
Consistent with findings of previous studies, TNBC when compared to 
Non-TNBC occur at a significantly younger age (Parise & Caggiano, 2017; Plasilova et 
al., Matt, Mozayen, Gress, & Tirona; Orucevic et al.; Llanos et al.; Banegas et al.; 
Ambrosone et al., 2014; Shinde et al., 2010; Chen et al., 2016; Bauer et al., 2007; 
Santebennur et al., 2008; Kwan et al., 2009; Sineshaw et al., 2014; Brown et al., 2008; 
Anders et al., 2011; Lund et al., 2008; Tawfik et al., 2010;). However, our study’s finding 
varied in that the median age is 58 years for TNBC whereas Tawfik et al. (2010), 
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reported 51 years as median age at diagnosis and Bauer et al. (2007) and Brown et al. 
(2008) reported the median age at diagnosis as 54 years. It needs to be noted that unlike 
our study, Bauer et al. and Brown et al. were single registry studies with cases diagnosed 
between 1999 and 2003/04 while Tawfik et al. (2010) included only African American 
and Caucasian women in their study. This could be a plausible reason for the difference 
in the median age finding. 
TNBC tumors when compared to Non-TNBC tumors present at later stages of 
disease (Lin et al., 2012; Llanos et al.; Rummel et al.; Parise & Caggiano, 2017; Rizzo et 
al., 2009; Brown et al., 2008; Bauer et al., 2007; Lund et al., 2010) and our study finding 
contrasted Zaky et al. (2011) and Trivers et al. (2009) in they did not observe statistically 
significant differences between TNBC and Non-TNBC groups. This could possibly be 
due to age restriction of the study population to 20-54 years, small sample numbers 
(n=476) (Trivers et al.) or sampling primarily based on a treatment, such as Breast 
Conservation Therapy (Zaky et al.). Most published studies had reported TNBC tumor 
sizes to be more than 2 centimeters in diameter at the time of presentation (Parise & 
Caggiano, 2017; Plasilova et al; Llanos et al.; Banegas et al.; Santebennur et al., 2008; 
Sineshaw et al., 2014; Lund et al., 2010; Kanaan et al., 2014). While our study supported 
this finding, we found statistical significance (<0.001) when comparing TNBC and 
Non-TNBC tumor sizes, 2cms versus 1.7 cms, respectively (Brown et al., 2008; Bauer et 
al., 2007; Tawfik et al., 2010).  
Consistent with published literature, TNBC tumors in this study presented with 
advanced tumor grades (Llanos et al.; Rummel et al.; Parise & Caggiano, 2017; Brown et 
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al.; Bauer et al.; Tawfik et al., Plasilova et al. 2016; Sineshaw et al.; Orucevic et al., 2015; 
Morris et al., 2007; Lund et al., 2009; Lund et al., 2008; Banegas et al; Zaky et al., 2011; 
Kanaan et al., 2014;). However, this study is the first to report statistically significant (p < 
0.001) differences between TNBC and Non-TNBC tumors for lymph node involvement 
as previous studies compared TNBC to Luminal type A cancer only (Plasilova et al., 
Llanos et al., 2015, Banegas et al., 2014). Consistent with previous findings (Plasilova et 
al., 2016), TNBC is associated with metastasis (p < 0.001). However, our study was the 
first to report metastatic findings for eight major races/ethnicities diagnosed in recent 
years. For a comparison of the treatment variable between TNBC and Non-TNBC tumors, 
major differences were noted for chemotherapy (36.6% versus 71% respectively) but 
only slight differences noted for radiation (49.4% versus 45.7% respectively) and surgery, 
although they all were statistically significant differences (p < 0.001). Chemotherapy data 
needs to be interpreted with caution due to the low sensitivity (68%) of the information 
provided by the SEER (Noone et al). Among TNBC cases, our study found 63.4% of 
women to not receive chemotherapy, but as SEER cautioned we need to pay attention to 
understand that the 63.4% is a collective grouping of those who did not receive 
chemotherapy and those on whom chemotherapy information is not known. This caution 
prevents researcher bias in interpreting the results. 
Consistent with previous studies, NH Black women were found to have 
significantly higher odds for TNBC compared to NH White women (Kwan et al., 2009; Lin 
et al., 2012; Sineshaw et al., 2014). Our study reported a 70% increased probability for 
Hispanics to develop TNBC compared to NH White women. Previous literature had 
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reported 17% probability of TNBC compared to the HR+/HER2- subtype only. Filipino 
and Vietnamese women had higher odds for TNBC, however they were non-significant 
findings. Further research targeting these ethnicities is needed to confirm our findings.  
Our study reported Asian Indian women less than 40 years of age to have higher 
odds for TNBC compared to NH White women. A previous study had reported NH Black 
women less than 40 years of age to be at increased risk for TNBC while our study did not 
find this to be at a level of significance (Anders et al., 2011). Our study reported 15% 
increased risk for NH Black women with Stage III cancer compared to NH White women 
with Stage III breast cancer to be TNBC.  
Also, previous studies that reported TNBC frequencies in Asian Indians always 
grouped them with women from Pakistan, Sri Lanka, Bangladesh, Nepal and Sikkim 
(Iqbal et al., 2015; Parise & Caggiano, 2014; C. Parise & Caggiano, 2016; Telli et al., 
2011) . Rao et al. (2011) and Plasilova et al. (2016) reported TNBC frequency for Asian 
Indians, but the sample from the Rao et al. (2011) study included women in Stages 0-II 
only. Plasilova et al. used a sample from a shorter time frame of two years compared to 
our study that included women with stages I-IV over four years. Our study is the first to 
show significant (p = 0.49) increased odds for TNBC among the Asian Indian women 
alone who are less than 40 years of age without grouping them with other ethnicities. NH 
Black women with stage III were reported to have a risk for death due to breast cancer 
death (Tao et al., 2015) . These findings among NH Black and Asian Indian women 
highlight the need for TNBC prevention through genetic counselling followed by testing 
(Rummel, Varner, Shriver, & Ellsworth, 2013). 
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 Deleterious mutations in BRCA 1 had been reported among TNBC women 
(Sharma et al., 2014; Lynce et al., 2015; Rummel et al., 2013; Sharma et al., 2014; 
Gonzalez-Angulo, et al. 2011). TNBC status is a predictor for BRCA 1/2 mutation on 
univariate analysis (Lynce et al.). Lynce et al. further reported that one in seven black 
women who underwent genetic counseling had a positive result for BRCA 1/2 mutation. 
Hence our findings urge healthcare providers to make referrals for genetic counselling 
and testing for the high-risk ethnic women 
Our study confirmed that TNBC women are at significantly (p = 0.001) higher 
odds to be in households with lower income (less than $5,000, in tens) compared to 
higher income levels (Sineshaw et al., 2014, Parise & Caggiano, 2014). NH Black 
women with median household incomes less than $5,000 (in tens) are at significant (p = 
.009) higher odds for TNBC compared to NH White women. Similarly, Chinese women 
with Median household income between $8,000 and $12,397 (in tens) are significantly 
4.5 times (p = 0.044) likely to be TNBC compared to women with income less than 
$5,000 (in tens). Other studies had used median household income along with education 
level, insurance status, and we do not have previous findings to compare with ( Parise & 
Caggiano, 2017; Sineshaw et al., 2014). Compared to women with insurance, uninsured 
women are more likely to be in TNBC group, findings similar to Sineshaw et al.  
Our study reported consistent findings related to TNBC tumor histology (ductal 
carcinoma) (Swede et al., 2011), tumor grade (higher grades) (Kanaan et al., 2014; Llanos 
et al., 2015; Orucevic et al., 2015; Sineshaw et al., 2014; Telli et al., 2011). We reported 
significantly 5, 40 and 42 times more likely to be Grades II, III, and IV respectively, 
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compared to grade I (p < 0.0001) whereas previous studies had only reported 10 to 20 times 
(Howlader et al., 2014; Llanos et al., 2015). NH Black women had significantly lesser odds 
for grade III tumors while Hispanic women had significantly lesser odds for Grade II and 
III compared to Grade I tumors (p = 0.10, 0.028, 0.04 respectively). Our results contrasted 
Parise et al. (2017) and Iqbal et al., (2015) and Banegas et al. (2014) who found higher odds 
for TNBC tumors to be higher grade for these ethnic women. Since NH Black and Hispanic 
women were at increased odds for lower grade tumors these women may benefit from early 
detection and plausible improved survival outcomes.   
TNBC women were 10% less likely (p < 0.00001) to receive radiation compared to 
those who received radiation. Our study reported NH Black women who did not receive 
radiation were significantly (p = 0.038) less likely to be TNBC. This finding needs to be 
confirmed by further research as a previously study reported no significance (Dawood et al., 
2009). 
In contrast to previously reported findings, our study reported significant higher 
odds (p < 0.0001) for TNBC tumors to be Stage I compared to Stage IV (Zaky et al., 2011). 
NH Black women with Stage III and Chinese women with Stage IV breast cancers are 1.15 
and 2.3 times significantly more likely to develop TNBC compared to NH White women (p 
= 0. 038, 0.027 respectively). Our findings supported the report by Chen and Li (2015) on 
African American women but contrasted their findings on Chinese women with stage IV 
tumors who were significantly more likely to be TNBC compared to NH White women (p 
= 0.027).  
Limitations 
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Firstly, the lack of detailed information on chemotherapy and hormone therapy on 
all cases. The chemotherapy information given from SEER included unknown cases for 
receiving chemotherapy along with those women who did not receive chemotherapy. 
Currently SEER is undertaking efforts to provide more information on chemotherapy 
details of patient. Secondly, clinical information on family history, BRCA gene testing 
results and demographic information such as educational and nativity status are 
unavailable in SEER data. Thirdly, we did not create a composite score for SES due to 
non-availability of individual’s income and education level. Finally, for the model 
prediction, the classification table gave 88.7% correct, but almost all cases were predicted 
to be in the non-TNBC group. 
Strengths of the study are that the proportion of foreign-born persons is higher 
among SEER cases compared to general U. S. population and the study’s interest was to 
examine the TNBC burden among Asian ethnicities. A large sample number, inclusion of 
eight major race/ethnicities of women more than 18 years of age was a strength of this 
study. This could also be the reason for our study to reach statistical significance of p < 
0.001 between the TNBC and non-TNBC group whereas some studies did not. Another 
strength of the study is the inclusion of Asian women subdivided into individual ethnic 
groups in identifying associations with TNBC and model prediction. 
In summary, significant differences exist between TNBC and non-TNBC groups 
for clinical and demographic characteristics of tumors. Ethnic differences exist among 
groups for clinical and demographic categories. For example, NH Black women are more 
likely to present with TNBC compared to NH White and Asian Indian women who are less 
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than 40 years of age, are significantly more likely to be in the TNBC group versus the 
non-TNBC group. Further research is warranted to confirm our study findings and to 
further explore the ethnic differences that exist between the groups. Clinically, these 
high-risk women need to be identified and followed for early detection of TNBC tumors. 
The literature cites a high frequency of TNBC tumors that had been self-detected compared 
to Luminal type A tumors (Llanos et al.; Lin et al., 2012;). While not a variable available 
for inclusion in this study, this approach could promote early detection in this high-risk 
group. Community educational programs need to be initiated to reach ethnic women to 
encourage self-assessment for early detection of these triple negative breast tumors.  
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CHAPTER 5 
CONCLUSIONS 
This chapter summarizes the main findings, discussions, limitations, implications, 
and recommendations of the dissertation. It presents and discusses the similarities and 
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differences between the three manuscripts. An explanation of how the study contributed 
to the extension of existing knowledge on the problem of TNBC in women of color and 
the interventionist track of Healthcare Genetics is included. Knowledge gaps are 
identified and an agenda is presented for future work. 
Findings from this Research 
Non-Hispanic/NH Black had the highest rate of 516.17 (per 100,000) followed by 
NH White women at 287.92, Hispanic women at 212.91, and 190.60 for Asian Pacific 
Islander women. Among NH Whites, women 70-74 years had the highest TNBC 
incidence rate followed by 65-69-year-old (35.84 and 33.65 per 100,000 respectively). 
Among NH Blacks, 60-64 years of age had the highest rate followed by 65-69 years of 
age (62.43 and 59.41 per 100,000 respectively). For Hispanic women, those 65-69 years 
of age had the highest rate followed by 70-74 years of age (24.81 and 22.54 per 100,000 
respectively), Asian/Pacific Islander was the only group who had the highest age-specific 
rate among women aged 80-84 years (22.084) followed by 65-69 years old women (20.73 
per 100,000).  
For phenotypic and treatment characteristics, differences among races/ethnicities 
were noted. NH Black women with TNBC had the highest frequency for: Stages III and 
IV (18.5% and 8% respectively); positive metastasis (8%); positive lymph node invasion 
(42%); and not having a surgical treatment (10.2%). Asian Indian women were: the 
youngest (median age at 47 years); had the highest frequency for grade III tumors 
(84.7%); to receive chemotherapy (85.5%); receive radiation (51.9%); who underwent 
surgery (95.4%); Korean women had the highest frequency (2.4%); for grade IV; and for 
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receiving no radiation (56.3%). All groups were similar in being ductal carcinoma for 
tumor histology. 
Among TNBC cases, NH Black women had the highest frequency (21.25%) 
followed by Asian Indian (12.96%), Hispanic (12.69%), Korean (12.1%), NH White 
(10.3%), Chinese (9.38%), Vietnamese (9.1%), and Filipino women (8.44%). Compared 
to non-TNBC women, TNBC women were observed to be youngest for median age at 
diagnosis (58 years), and higher proportions to be uninsured, in low socio economic 
status, with median household income between $1,915 to $5,999 (in tens), tumor stages II 
and above, larger tumor sizes, tumor grades III and above, infiltrating ductal carcinoma, 
positive for metastasis, and to receive chemotherapy for treatment. Future research is 
needed to examine the relationship between low SES and TNBC phenotypic 
characteristics among the eight race/ethnic groups. 
Using a binary logistic regression model the results predicted Hispanic women 
and Asian Indian women less than 40 years of age, NH Black Stage III women, NH 
Black women with income less than $5000 (in tens), Hispanics with Grade I, women with 
Stage I tumors; Chinese women with median household income $8000-12397 (in tens) 
had higher odds to be TNBC. Among treatment variable categories, only radiation 
(receiving none) was found to be a significant predictor (p < 0.001) for TNBC.  
Limitations 
The study had few limitations and they are related to sample information available 
from SEER. Firstly, there was a lack of population count for the five Asian ethnicities- 
Chinese, Asian Indian, Filipina, Korean and Vietnamese preventing the calculation of the 
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respective incidence rates which prevented us from identifying the TNBC burden among 
those populations of women. Secondly, there was a lack of information on the nativity 
status of the women (U.S. or foreign-born), completed education level (less than high 
school, high school, college, graduate), chemotherapy, and hormone therapy information. 
These data will add value to the clinical assessment of TNBC cases. SEER is currently 
undertaking efforts to add that information to its records. Thirdly, lack of family history, 
and results from genetic tests hindered the inclusion of significant variables in the 
prediction model. Finally, the large sample size could be a limitation itself as statistical 
tests reach significance due to the large numbers and presence of a true 
association/relationship needs to be verified (Kaplan, Chambers, & Glasgow, 2014).  
Discussion 
 The most recent epidemiological results available on TNBC were reported in this 
study. Previously published studies reported on cases diagnosed in the years 2006-2009 
(Clarke et al., 2012) and in 2010 (Howlader et al., 2014). Our study included women 
diagnosed, from 2010-2013. Hence the age-adjusted incidence rate and age-specific 
incidence rates are the most recent and not published prior to 2014. Although ranking 
(highest to lowest) of races/ethnicities for age-specific rates is the same as previously 
published studies (Kohler et al., 2015; Plasilova et al., 2016), there is a change in the peak 
age for TNBC incidence among NH Black, NH White, Hispanic, and Asian / Pacific 
Islander women. 
  The Asian Indian population is one of the fastest growing groups in the U.S., 
~70% increase from 2000 to 2010 (Hoeffel, Rastogi, Kim, & Shahid, 2012). Only since 
167 
 
2010 has SEER recorded Asian Indian women as a separate ethnicity with previously 
published studies including Pakistani, Bangladeshi, Nepalese, Sikkimese, or Sri Lankan 
women grouped with Asian Indian women; Vietnamese women were also grouped with 
neighboring countries as “South Asian” women in research studies (Parise & Caggaino, 
2016). However, our study provided phenotypic and treatment information for TNBC that 
was previously unavailable on Asian Indian and Vietnamese women as well as for six 
other groups.   
This dissertation study is the first to show evidence on TNBC specific frequency 
among Asian ethnicities as previous studies published on Indian subcontinent women or 
Asian Pacific Islander women (Parise & Caggiano, 2016; Parise & Caggiano, 2014; 
Plasilova et al., 2016). Our study found (Chapter 4 results) Asian Indians ranked second 
in TNBC frequency next to NH Black, followed by Hispanic, Korean, NH White, 
Chinese, Vietnamese, and Filipina women. Asian Indian women less than 40 years were 
at higher odds for TNBC, a new finding. Unlike previously reported results, our study 
found Chinese women less frequently were diagnosed with TNBC compared to NH 
White. Chinese women with a median Household income between $8,000-12,397, and 
Chinese women with Stage IV tumors had higher odds for TNBC, again were new 
findings. This contrasted with the results of Chen and Li’s (2015) study. Our report of a 
significant association between TNBC and the median household income variable was 
also in contrast to other previous studies (Llanos et al., 2015, Dolle et al.). 
A significant association was found between insurance status and TNBC, unlike 
previous studies (Llanos et al.; Telli et al., 2011; Trivers et al., 2009; Banegas et al., 
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2014). Also, previous studies reported median age for TNBC as 51 years (Tawfik et al.), 
54 years (Bauer et al., 2008; Brown et al., 2008), whereas our study reported a median 
age of 58 years. The higher median age reflects the higher age-specific incidence rates in 
the age-groups 60-64, 65-69 years, and 70-74 years.  
Consistent with previous literature, NH Black women with Stage III disease were 
at higher odds for it to be TNBC (Chen & Li, 2015). NH Black with an income less than 
$5,000 as a TNBC predictor is a new finding in our study. NH Black women with a 
Grade III tumor or Hispanic women with Grades II and III tumors were found to be 
significant predictors for TNBC, but these variables were less likely to predict TNBC 
compared to non-TNBC tumors.  
In contrast to previously published literature (Zaky et al., 2011; Dawood et al., 
2009; Iqbal et al., 2015), our study reported significant differences among the eight 
race/ethnic groups for the demographic and phenotypic characteristics. Also, Stage I but 
not Stage II, III or IV as published in the literature (Telli et al., 2011), was a significant 
predictor for women to be in the TNBC group. Telli et al. sampled women from the 
California Cancer Registry (diagnosed cases 2002-2007) to predict odds for TNBC 
compared to HR+/HER2- women and found Stages II and above to be highly likely to be 
TNBC, but was a non-significant finding. 
Similarities and differences between the three manuscripts 
 The similarities between chapter three and chapter four manuscripts are in terms 
of the sample and the primary problem of study. Chapter three and four provided 
information on eight groups of women (Non-Hispanic White, Non-Hispanic Black, 
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Hispanic, Filipina, Chinese, Asian Indian, Korean and Vietnamese) with TNBC. The two 
manuscripts discuss information on cases diagnosed from 2010 to 2013. All information 
is from a single source which is the SEER data. 
 There are many differences identified between the three manuscripts. Chapter 
two synthesized the information retrieved from literature published from 2007 (January) 
to 2017 (February). Chapter three reported age-adjusted and age-specific incidence data 
on TNBC for the eight groups, adjusted to Standard United States 2000 population. It 
also provided information on the phenotypic, demographic, and treatment characteristics 
of TNBC cases. Chapter four reported findings on TNBC phenotypic, demographic, and 
treatment characteristics compared to Non-TNBC cases, and reported odds for TNBC 
based on a prediction model. Chapter four included Non-TNBC cases in the sample, 
whereas manuscript three included TNBC cases only. These are the major similarities and 
differences noted between the three manuscripts. 
Coherent Body of Work 
 Chapter two discussed the literature search that was done on published journal 
articles on the selected problem. It provided information that was already available about 
the problem, the significance of the problem, and available information on 
races/ethnicities. Knowledge gaps were identified and the research proposal was 
developed. Manuscript three discussed the findings from the study that answered two 
research questions- incidence of TNBC, both age-adjusted and age-specific, as well as the 
clinical presentation and pathologic features of TNBC. It was focused on the eight 
race/ethnic groups of interest. Chapter four manuscript discussed the findings about 
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TNBC, but in comparison with Non-TNBC cases. All cases were compared on the 
different variables, and were used to develop a prediction model. The first model was an 
unadjusted model that used the race/ethnic information only, but the successive models 
included many other variables and the interaction effects. The final model included 
significant predictor variables and the interaction effects. From the model, the higher and 
lesser odds for developing TNBC was obtained.  
Contribution to the Knowledge regarding the problem and the specialty area of 
HCG 
 Our study’s sample is the first to include TNBC and Non-TNBC cases from all 
18 SEER registries for the years 2010 to 2013, ages 18 years and above, and all stages of 
TNBC. Our study contributed knowledge regarding TNBC incidence rates on major races 
(NH White, NH Black, and Hispanic) and Asian sub-ethnicities (Chinese, Asian Indian, 
Filipina, Vietnamese, and Korean) in the U. S.  
 Our study is the first to report statistically significant differences between ethnic 
groups for TNBC stage, tumor grade, tumor histology, tumor size, lymph node 
involvement, metastasis, and treatment. In contrast to published literature, our study 
reported significant association of TNBC with insurance status and median household 
income. In contrast to previously reported findings, our study reported significantly 
higher odds (p < 0.0001) for TNBC tumors to be Stage I compared to Stage IV. 
Consistent with previous findings (Plasilova et al.), TNBC is associated with metastasis (p 
< 0.001). However, our study was the first to report findings for eight major 
races/ethnicities diagnosed in the recent years for metastasis 
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TNBC phenotypic differences among ethnicities such as Hispanic and Asian 
sub-groups were not available in the literature when compared to NH White and NH 
Black populations. We added more knowledge to TNBC among Asian subgroups: 
Chinese women with stage IV tumors significantly more likely to be TNBC compared to 
NH White women (p = 0.027). Our study also found Asian Indian women to have highest 
frequency next to NH Black women and significant (p = 0.49) increased odds for TNBC 
compared to NH White women. Our study reported a 70% increased probability for 
Hispanics for TNBC compared to NH White women and previous literature had reported 
17% probability compared to HR+/HER2. 
The study contributed to the “Interventionist” specialty track of HCG by 
providing information on groups of population on an issue that has genetic risk factor as 
per literature. The study contributed by laying the foundation for addressing the problem 
“TNBC disparity among ethnicities.” The study highlighted the current burden of TNBC 
and statistically proved that there are significant differences between ethnicities for 
phenotypic characteristics, demographics, and treatment options. These differences 
impact the outcome of the disease. A HCG interventionist can use this information to 
counsel women who may fall into the high-risk category, based on the predictors from 
our adjusted prediction model. Applying the Health Belief Model to our problem of 
interest, a person can perceive their susceptibility only when cancer statistics are 
available specific to them. Now that the cancer statistics are available from our study, 
women from Asian, Hispanic and Black races/ethnicities can be provided with this 
information and alerted for their high-risk status. As per the Health Belief Model, when 
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an individual perceives the seriousness of the disease, self-efficacy plays a role. The 
individual can adopt a healthy behavior, which could be preventive or early detection. 
Using the study findings along with other risk assessment scales that are available, the 
women can be presented with information on genetic testing available for TNBC. A HCG 
interventionist can also be involved by using the study findings as an educational material 
to encourage a person towards an early detection behavior such as consistent high-risk 
screening practices (cues to action).  
Knowledge Gaps 
 Firstly, we do not have information on incidence rate for the Asian 
sub-ethnicities from the recent years. The study provided TNBC frequency data, but not 
the adjusted incidence rate as SEER does not have the population count for the Asian 
sub-ethnicities. Secondly, although a countrywide database, SEER does not provide 
information on variables such as education, family history, genetic tests, country of origin, 
metabolic syndrome, reproductive factors (breast feeding, hormone therapy information, 
parity, and others) and lifestyle factors such as smoking, alcohol consumption, caffeine 
intake. Thirdly, the SEER variables that were county attributes from the American 
Community Survey may only reflect the individual’s household income, poverty percent 
but not provide accuracy. The education level and annual income of individual versus a 
county could best contribute to the TNBC prediction model by providing more accuracy. 
Recommendations and Implications for Future Research 
Clinical Recommendations 
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Literature suggested that healthcare providers may not have the necessary 
understanding to recommend genetic counseling and genetic testing to underserved and 
minority women (Ricks-Santi & McDonald, 2016). A healthcare provider’s referral and a 
woman’s race/ethnicity were significant predictors for genetic testing (Ricks-Santi and 
McDonald; Cragun et al., 2015; Thompson et al., 2012) Based on our study, compared to 
NH White, NH Black and Hispanics were at increased risk for TNBC. Four studies done 
among TNBC cases reported prevalence on BRCA mutation, ranging from 9% to 21.4% 
(Gonzalez-Angulo et al., 2011; Lynce et al., 2015; Rummel et al., 2013; Sharma et al., 
2014) Using the findings of the study, along with evidence that BRCA 1 mutations are 
prevalent among TNBC cases, healthcare providers should clinically identify high-risk 
women for TNBC and recommend genetic testing and genetic counselling.  
The literature stated that a majority (60%) of TNBC tumors are self-detected (Lin et 
al., 2012; Llanos et al., 2015), almost one-third of tumors are detected via mammogram, 
and a majority present with symptoms when compared with Luminal A cancers (Lin et al., 
2012). Hence clinicians should clinically screen for high-risk women based on 
race/ethnicity, age at diagnosis, insurance status, and median income level. Although 
insurance status and median income level has been reported, in the literature, to have no 
significant association, we include it as our study found significant association. These 
women should be advised for regular screening based on the U.S. Preventive Services 
Task Force Recommendation Statement (Siu, 2016). 
Women in obstetrics and Gynecology, oncology settings had higher rates for 
physician recommendation and genetic counseling (Armstrong et al., 2015; Thompson et 
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al., 2012), whereas women with less education, Black women with no insurance, or 
foreign-born Black women were significantly less likely to receive the recommendations 
(Thompson et al.). The study’s results suggest that clinicians should re-evaluate their 
approach in reaching the Asian sub-ethnicities, NH Black, and Hispanic women.   
Educational Recommendations 
Physicians should be educated on utilization of genetic tools and make referrals for 
personalized cancer treatment (Ricks-Santi & McDonald). Clinical services in hospitals 
and other institutions should develop educational materials in the language of the ethnic 
minorities to provide them information on how TNBC can be prevented, detected early, 
and treated. Community educational programs should be conducted to increase the 
awareness about TNBC, its incidence, prophylactic treatment across all ages of women. 
Educational programs need to be developed to equip healthcare providers with 
information on incidence, clinic-pathologic characteristics of TNBC, and genetic 
susceptibility. MacNew et al. (2010) recommended educational efforts on BRCA testing 
and its benefits to target less educated and minority groups. 
Future Research 
The recommendations for future research include to: 
1. calculate incidence rate using a state registry or a national database that has 
population count for Asian sub-ethnicities to obtain individual rates on Asian 
sub-groups 
2. further explore the role of TNBC risk factors including, but not limited to, genetic 
mutations, family history, nativity status, age, income, education, insurance, 
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reproductive factors (menarche, menopause, parity, breast feeding, oral 
contraceptive pill usage, hormone therapy), metabolic syndrome, obesity, lifestyle 
(exercise, smoking, alcohol) and others at a large-scale level.  
3. develop a TNBC risk assessment scale using the predictors from the model and 
other significant variables to identify high-risk women of color. 
4. explore validity of ‘persons below poverty percent’ as a measure for SES and 
confirm our findings. 
5. assess for differences between TNBC cases and controls for TNBC phenotypic 
and demographic characteristics, for usage of services such as clinical breast 
examination, mammogram screening, Breast Ultrasound, Breast MRI along with 
the study variables among the eight races/ethnicities. 
6. assess stage I as a significant indicator for high-risk status in a smaller sample size 
study 
7. develop qualitative study to assess an individual’s perception of risk before and 
after presenting the TNBC incidence and frequency information and to understand 
the process of making decisions towards genetic testing and genetic counseling.  
 
Summary 
This chapter summarized the main findings, discussions, limitations, implications, 
and recommendations of the dissertation. Similarities and differences between the three 
manuscripts were presented and discussed. An explanation of contributions to existing 
knowledge on the problem of TNBC in women of color and the interventionist track of 
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Healthcare Genetics was included. Knowledge gaps were identified and an agenda was 
presented for future work. 
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